Publika - Scientific publications from Oslo University Hospital

RSS feed RSS

Publications by Jahn Marthin Nesland

565 publications found

Original articles

Wang Z, Førsund MS, Trope CG, Nesland JM, Holm R, Slipicevic A (2018)
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
Cancer Med, 7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769

Fan Z, Li L, Li X, Zhang M, Zhong Y, Li Y, Yu D, Cao J, Zhao J, Xiaoming Deng, Zhang M, Jian-Guo Wen, Liu Z, Goscinski MA, Berge V, Nesland JM, Suo Z (2018)
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat diet
RSC Adv, 8 (30), 16636-16644
DOI 10.1039/c8ra00253c, PubMed 35540547

Li X, Grigalavicius M, Li Y, Li X, Zhong Y, Huang R, Yu D, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells
Tumour Biol, 39 (8), 1010428317713671
DOI 10.1177/1010428317713671, PubMed 28789597

Li X, Han G, Li X, Kan Q, Fan Z, Li Y, Ji Y, Zhao J, Zhang M, Grigalavicius M, Berge V, Goscinski MA, Nesland JM, Suo Z (2017)
Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells
Oncotarget, 8 (28), 46363-46380
DOI 10.18632/oncotarget.18199, PubMed 28624784

Li X, Lu J, Kan Q, Li X, Fan Q, Li Y, Huang R, Slipicevic A, Dong HP, Eide L, Wang J, Zhang H, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547

Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2017)
Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study
Prostate, 77 (8), 859-865
DOI 10.1002/pros.23326, PubMed 28240424

Zhong Y, Li X, Ji Y, Li X, Li Y, Yu D, Yuan Y, Liu J, Li H, Zhang M, Ji Z, Fan D, Wen J, Goscinski MA, Yuan L, Hao B, Nesland JM, Suo Z (2017)
Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers
Oncotarget, 8 (8), 13344-13356
DOI 10.18632/oncotarget.14527, PubMed 28076853

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 8 (4), 7208-7213
DOI 10.18632/oncotarget.14800, PubMed 28179591

Li Y, Li X, Kan Q, Zhang M, Li X, Xu R, Wang J, Yu D, Goscinski MA, Wen JG, Nesland JM, Suo Z (2017)
Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas
Oncotarget, 8 (1), 1058-1073
DOI 10.18632/oncotarget.13717, PubMed 27911865

Li X, Li Y, Han G, Li X, Ji Y, Fan Z, Zhong Y, Cao J, Zhao J, Mariusz G, Zhang M, Wen J, Nesland JM, Suo Z (2016)
Establishment of mitochondrial pyruvate carrier 1 (MPC1) gene knockout mice with preliminary gene function analyses
Oncotarget, 7 (48), 79981-79994
DOI 10.18632/oncotarget.13210, PubMed 27835892

Li X, Ji Y, Han G, Li X, Fan Z, Li Y, Zhong Y, Cao J, Zhao J, Zhang M, Wen J, Goscinski MA, Nesland JM, Suo Z (2016)
MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
BMC Cancer, 16 (1), 894
DOI 10.1186/s12885-016-2941-6, PubMed 27852261

Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, Fan Z, Fan H, Yuan L, Xu B, Yuan Y, Zhang H, Ji Z, Wen JG, Zhang M, Nesland JM, Suo Z (2016)
Generation of TALEN-mediated FH knockout rat model
Oncotarget, 7 (38), 61656-61669
DOI 10.18632/oncotarget.11429, PubMed 27556703

Yu D, Holm R, Goscinski MA, Trope CG, Nesland JM, Suo Z (2016)
Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study
Am J Cancer Res, 6 (9), 2088-2097
PubMed 27725913

Li Y, Huang R, Li X, Li X, Yu D, Zhang M, Wen J, Goscinski MA, Trope CG, Nesland JM, Suo Z (2016)
Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma
Am J Cancer Res, 6 (9), 2076-2087
PubMed 27725912

Li Y, Li X, Li X, Zhong Y, Ji Y, Yu D, Zhang M, Wen JG, Zhang H, Goscinski MA, Nesland JM, Suo Z (2016)
PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence
Oncotarget, 7 (33), 53837-53852
DOI 10.18632/oncotarget.10782, PubMed 27462778

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2016)
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 7 (26), 40297-40313
DOI 10.18632/oncotarget.9610, PubMed 27248169

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2016)
Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality
Prostate, 76 (12), 1088-94
DOI 10.1002/pros.23192, PubMed 27271973

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843

Ji Y, Li X, Li Y, Zhong Y, Cao J, Xu R, Wang J, Zhou F, Li X, Yu D, Wen JG, Goscinski MA, Zhang M, Nesland JM, Suo Z (2016)
Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell Carcinoma
Anticancer Res, 36 (1), 343-9
PubMed 26722063

Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, Fan H, Yuan Y, Ji Z, Qiao B, Wen JG, Zhang M, Kvalheim G, Nesland JM, Suo Z (2015)
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro
Oncotarget, 6 (40), 42687-703
DOI 10.18632/oncotarget.5883, PubMed 26528857

Goscinski MA, Xu R, Zhou F, Wang J, Yang H, Huang R, Li Y, Larsen SG, Giercksky KE, Nesland JM, Suo Z (2015)
Nuclear, cytoplasmic, and stromal expression of ZEB1 in squamous and small cell carcinoma of the esophagus
APMIS, 123 (12), 1040-7
DOI 10.1111/apm.12473, PubMed 26547370

Zhong Y, Li X, Yu D, Li X, Li Y, Long Y, Yuan Y, Ji Z, Zhang M, Wen JG, Nesland JM, Suo Z (2015)
Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro
Oncotarget, 6 (35), 37758-69
DOI 10.18632/oncotarget.5386, PubMed 26413751

Attramadal CG, Kumar S, Boysen ME, Dhakal HP, Nesland JM, Bryne M (2015)
Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas
Anticancer Res, 35 (11), 6111-20
PubMed 26504037

Li X, Huang R, Li RH, Trope CG, Nesland JM, Suo Z (2015)
Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients
Mol Clin Oncol, 4 (1), 18-22
DOI 10.3892/mco.2015.662, PubMed 26870350

Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort
Prostate, 76 (2), 207-14
DOI 10.1002/pros.23112, PubMed 26477789

Zhong Y, Huang R, Li X, Xu R, Zhou F, Wang J, Fan H, Goscinski M, Zhang M, Wen JG, Nesland JM, Suo Z (2015)
Decreased Expression of PDHE1α Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma
Anticancer Res, 35 (10), 5533-8
PubMed 26408721

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2015)
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study
BMC Cancer, 15, 502
DOI 10.1186/s12885-015-1513-5, PubMed 26148881

Huang R, Wang J, Zhong Y, Liu Y, Stokke T, Trope CG, Nesland JM, Suo Z (2015)
Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties
Anticancer Res, 35 (7), 3743-53
PubMed 26124317

Goscinski MA, Larsen SG, Giercksky KE, Nesland JM, Suo ZH (2015)
PDGFR-alpha and CD117 Expression Pattern in Esophageal Carcinomas
Anticancer Res., 35 (7), 3793-3799

Goscinski MA, Larsen SG, Giercksky KE, Nesland JM, Suo Z (2015)
PDGFR-α and CD117 Expression Pattern in Esophageal Carcinomas
Anticancer Res, 35 (7), 3793-9
PubMed 26124324

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R (2015)
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
PLoS One, 10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The prognostic value of reactive stroma on prostate needle biopsy: a population-based study
Prostate, 75 (6), 662-71
DOI 10.1002/pros.22957, PubMed 25620661

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K (2014)
Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience
Scand J Urol, 49 (3), 218-23
DOI 10.3109/21681805.2014.982168, PubMed 25428750

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994

Attramadal CG, Halstensen TS, Dhakal HP, Ulekleiv CH, Boysen ME, Nesland JM, Bryne M (2014)
High nuclear SOX2 expression is associated with radiotherapy response in small (T1/T2) oral squamous cell carcinoma
J Oral Pathol Med, 44 (7), 515-22
DOI 10.1111/jop.12261, PubMed 25224722

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
BMC Cancer, 14, 602
DOI 10.1186/1471-2407-14-602, PubMed 25139714

Cunderlíková B, Vasovič V, Randeberg LL, Christensen E, Warloe T, Nesland JM, Peng Q (2014)
Modification of extracorporeal photopheresis technology with porphyrin precursors. Comparison between 8-methoxypsoralen and hexaminolevulinate in killing human T-cell lymphoma cell lines in vitro
Biochim Biophys Acta, 1840 (9), 2702-8
DOI 10.1016/j.bbagen.2014.05.020, PubMed 24915603

Bruun J, Kolberg M, Nesland JM, Svindland A, Nesbakken A, Lothe RA (2014)
Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series
Front Oncol, 4, 118
DOI 10.3389/fonc.2014.00118, PubMed 24904831

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056

Wu Q, Shi H, Holm R, Li X, Trope C, Nesland JM, Suo Z (2014)
Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma
Anticancer Res, 34 (2), 859-65
PubMed 24511023

Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K (2014)
The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy
Urol Int, 93 (3), 289-95
DOI 10.1159/000362342, PubMed 25170745

Huang R, Ma Y, Holm R, Trope CG, Nesland JM, Suo Z (2013)
Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations
PLoS One, 8 (12), e83238
DOI 10.1371/journal.pone.0083238, PubMed 24386165

Dhakal HP, Nesland JM, Førsund M, Trope CG, Holm R (2013)
Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact
BMC Cancer, 13, 506
DOI 10.1186/1471-2407-13-506, PubMed 24165149

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
The clinical impact of mean vessel size and solidity in breast carcinoma patients
PLoS One, 8 (10), e75954
DOI 10.1371/journal.pone.0075954, PubMed 24146798

Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013)
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide
J Clin Endocrinol Metab, 98 (11), E1730-9
DOI 10.1210/jc.2013-2145, PubMed 24092823

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518

Shahzidi S, Brech A, Sioud M, Li X, Suo Z, Nesland JM, Peng Q (2013)
Lamin A/C cleavage by caspase-6 activation is crucial for apoptotic induction by photodynamic therapy with hexaminolevulinate in human B-cell lymphoma cells
Cancer Lett, 339 (1), 25-32
DOI 10.1016/j.canlet.2013.07.026, PubMed 23916608

Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R (2013)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
BMC Cancer, 13, 288
DOI 10.1186/1471-2407-13-288, PubMed 23767999

Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K (2013)
Dendritic and lymphocytic cell infiltration in prostate carcinoma
Histol Histopathol, 28 (12), 1621-8
DOI 10.14670/HH-28.1621, PubMed 23729368

Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, Wu MC, Bin Abdul Hadi LH, Soong R, Choolani M, Davidson B, Nesland JM, Wang LZ, Matsumura N, Mandai M, Konishi I, Goh BC, Chang JT, Thiery JP, Mori S (2013)
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
EMBO Mol Med, 5 (7), 1051-66
DOI 10.1002/emmm.201201823, PubMed 23666744

Goscinski MA, Nesland JM, Giercksky KE, Dhakal HP (2013)
Primary tumor vascularity in esophagus cancer. CD34 and HIF1-α expression correlate with tumor progression
Histol Histopathol, 28 (10), 1361-8
DOI 10.14670/HH-28.1361, PubMed 23653235

Fan H, Yuan Y, Wang J, Zhou F, Zhang M, Giercksky KE, Nesland JM, Suo Z (2013)
CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome
Histopathology, 62 (7), 1028-37
DOI 10.1111/his.12111, PubMed 23570416

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B (2013)
Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
Breast Cancer Res Treat, 138 (2), 485-97
DOI 10.1007/s10549-013-2439-8, PubMed 23456230

Lilleby W, Stensvold A, Mills IG, Nesland JM (2013)
Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients
Int J Cancer, 133 (1), 149-55
DOI 10.1002/ijc.28002, PubMed 23280694

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
PLoS One, 8 (7), e70558 (Retracted)
DOI 10.1371/journal.pone.0070558, PubMed 23936228

Holm R, Førsund M, Nguyen MT, Nesland JM, Trope CG (2013)
Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma
PLoS One, 8 (4), e61273
DOI 10.1371/journal.pone.0061273, PubMed 23580324

Liu J, Fan H, Ma Y, Liang D, Huang R, Wang J, Zhou F, Kan Q, Ming L, Li H, Giercksky KE, Nesland JM, Suo Z (2013)
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas
PLoS One, 8 (2), e56141
DOI 10.1371/journal.pone.0056141, PubMed 23409141

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
Histol Histopathol, 27 (10), 1315-25
DOI 10.14670/HH-27.1315, PubMed 22936450

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
DOI 10.1038/bjc.2012.293, PubMed 22782346

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
Histopathology, 61 (3), 350-64
DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749

Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z (2012)
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
DOI 10.1186/1471-2407-12-201, PubMed 22642602

Eide N, Hoifødt HK, Nesland JM, Faye RS, Qvale GA, Faber RT, Jebsen P, Kvalheim G, Fodstad Ø (2012)
Disseminated tumour cells in bone marrow of patients with uveal melanoma
Acta Ophthalmol, 91 (4), 343-8
DOI 10.1111/j.1755-3768.2012.02449.x, PubMed 22632270

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
Int J Cancer, 131 (11), 2528-36
DOI 10.1002/ijc.27566, PubMed 22473715

Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K (2012)
Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Int J Urol, 19 (8), 749-56
DOI 10.1111/j.1442-2042.2012.03017.x, PubMed 22487487

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, Nesland JM, Suo Z (2012)
Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines
Tumour Biol, 33 (4), 967-78
DOI 10.1007/s13277-012-0325-3, PubMed 22252524

Casar-Borota O, Fougner SL, Bollerslev J, Nesland JM (2012)
KIT protein expression and mutational status of KIT gene in pituitary adenomas
Virchows Arch, 460 (2), 171-81
DOI 10.1007/s00428-011-1185-8, PubMed 22213031

Mikalsen LT, Dhakal HP, Bruland OS, Nesland JM, Olsen DR (2011)
Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections
Anticancer Res, 31 (12), 4053-60
PubMed 22199261

Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K (2011)
Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies
BJU Int, 110 (2 Pt 2), E69-75
DOI 10.1111/j.1464-410X.2011.10759.x, PubMed 22093091

Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO (2011)
Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer
BJU Int, 109 (10), 1489-94
DOI 10.1111/j.1464-410X.2011.10583.x, PubMed 21933333

Davidson B, Stavnes HT, Risberg B, Nesland JM, Wohlschlaeger J, Yang Y, Shih IeM, Wang TL (2011)
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
Hum Pathol, 43 (5), 684-94
DOI 10.1016/j.humpath.2011.06.015, PubMed 21937081

Shahzidi S, Cunderlíková B, Więdłocha A, Zhen Y, Vasovič V, Nesland JM, Peng Q (2011)
Simultaneously targeting mitochondria and endoplasmic reticulum by photodynamic therapy induces apoptosis in human lymphoma cells
Photochem Photobiol Sci, 10 (11), 1773-82
DOI 10.1039/c1pp05169e, PubMed 21881674

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J (2011)
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
EJNMMI Res, 1 (1), 18
DOI 10.1186/2191-219X-1-18, PubMed 22214432

Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O (2011)
B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes
Int J Cancer, 130 (10), 2282-90
DOI 10.1002/ijc.26238, PubMed 21671471

Ågesen TH, Berg M, Clancy T, Thiis-Evensen E, Cekaite L, Lind GE, Nesland JM, Bakka A, Mala T, Hauss HJ, Fetveit T, Vatn MH, Hovig E, Nesbakken A, Lothe RA, Skotheim RI (2011)
CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer
Genes Immun, 12 (8), 653-62
DOI 10.1038/gene.2011.43, PubMed 21716316

Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M (2011)
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation
Mol Cancer Ther, 10 (6), 960-71
DOI 10.1158/1535-7163.MCT-11-0072, PubMed 21518725

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
Disseminated tumour cells as a prognostic biomarker in colorectal cancer
Br J Cancer, 104 (9), 1434-9
DOI 10.1038/bjc.2011.97, PubMed 21448171

Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø (2011)
Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
Int J Cancer, 129 (3), 742-50
DOI 10.1002/ijc.25922, PubMed 21225632

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis
Clin Cancer Res, 17 (9), 2967-76
DOI 10.1158/1078-0432.CCR-10-2515, PubMed 21415211

Yuan Y, Dong HP, Nymoen DA, Nesland JM, Wu C, Davidson B (2011)
PINCH-2 expression in cancers involving serosal effusions using quantitative PCR
Cytopathology, 22 (1), 22-9
DOI 10.1111/j.1365-2303.2010.00757.x, PubMed 20500520

Wang Z, Nesland JM, Suo Z, Trope CG, Holm R (2011)
The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors
PLoS One, 6 (9), e24843
DOI 10.1371/journal.pone.0024843, PubMed 21935479

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z (2011)
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties
PLoS One, 6 (12), e29170 (Retracted)
DOI 10.1371/journal.pone.0029170, PubMed 22216200

Čunderlíková B, Vasovič V, Sieber F, Furre T, Borgen E, Nesland JM, Peng Q (2010)
Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma
Bone Marrow Transplant, 46 (8), 1118-27
DOI 10.1038/bmt.2010.277, PubMed 21057550

Khouja MH, Baekelandt M, Sarab A, Nesland JM, Holm R (2010)
Limitations of tissue microarrays compared with whole tissue sections in survival analysis
Oncol Lett, 1 (5), 827-831
DOI 10.3892/ol_00000145, PubMed 22966388

Servoll E, Saeter T, Vlatkovic L, Nesland J, Waaler G, Beisland HO (2010)
Does a tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer?
Scand J Urol Nephrol, 44 (4), 217-22
DOI 10.3109/00365591003720283, PubMed 20367396

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Wang Z, He W, Yang G, Wang J, Wang Z, Nesland JM, Holm R, Suo Z (2010)
Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma
BMC Cancer, 10, 352
DOI 10.1186/1471-2407-10-352, PubMed 20602752

Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813

Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2010)
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
Breast Cancer Res Treat, 125 (3), 729-38
DOI 10.1007/s10549-010-0911-2, PubMed 20449649

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R (2010)
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome
Oncol Rep, 23 (4), 1045-52
DOI 10.3892/or_00000731, PubMed 20204290

Čunderlíková B, Vasovič V, Sieber F, Furre T, Nesland JM, Peng Q (2010)
Hexaminolevulinate-mediated photodynamic purging of leukemia cells from BM
Bone Marrow Transplant, 45 (10), 1553-61
DOI 10.1038/bmt.2009.382, PubMed 20118993

Nesland JM, Johannessen JV (2010)
Ultrastructural Pathology: 30 years young
Ultrastruct Pathol, 34 (1), 1
DOI 10.3109/01913120903526759, PubMed 20070146

Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH (2010)
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab
Eur J Nucl Med Mol Imaging, 37 (1), 93-102
DOI 10.1007/s00259-009-1197-7, PubMed 19593562

He W, Wang Z, Wang Q, Fan Q, Shou C, Wang J, Giercksky KE, Nesland JM, Suo Z (2009)
Expression of HIWI in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis
BMC Cancer, 9, 426
DOI 10.1186/1471-2407-9-426, PubMed 19995427

Lü X, Li H, Xu K, Nesland JM, Suo Z (2009)
MUC-1-/ESA+ progenitor cells in normal, benign and malignant human breast epithelial cells
Histol Histopathol, 24 (11), 1381-90
DOI 10.14670/HH-24.1381, PubMed 19760587

Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjørang O, Wu C, Nesland JM, Davidson B (2009)
Tenascin-X is a novel diagnostic marker of malignant mesothelioma
Am J Surg Pathol, 33 (11), 1673-82
DOI 10.1097/PAS.0b013e3181b6bde3, PubMed 19738457

Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B (2009)
Breast carcinoma cells in primary tumors and effusions have different gene array profiles
J Oncol, 2010, 969084
DOI 10.1155/2010/969084, PubMed 19680458

Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM (2009)
Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count
Histol Histopathol, 24 (8), 1049-59
DOI 10.14670/HH-24.1049, PubMed 19554512

Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H (2009)
Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome
Oncol Rep, 22 (1), 11-5
DOI 10.3892/or_00000399, PubMed 19513498

Bassarova A, Trøen G, Fosså A, Ikonomou IM, Beiske K, Nesland JM, Delabie J (2009)
Transformation of B cell lymphoma to histiocytic sarcoma: somatic mutations of PAX-5 gene with loss of expression cannot explain transdifferentiation
J Hematop, 2 (3), 135-41
DOI 10.1007/s12308-009-0031-2, PubMed 19669194

Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM, Suo Z (2009)
Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma
Anticancer Res, 29 (4), 1233-41
PubMed 19414369

Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009)
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
Histopathology, 54 (3), 355-64
DOI 10.1111/j.1365-2559.2009.03231.x, PubMed 19236512

Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506

Furre IE, Nesland JM, Peng Q (2009)
Apoptotic induction by photodynamic therapy using Hexaminolevulinate with a literature review
PROC SPIE, 7380, 73800X
DOI 10.1117/12.823956

Goscinski MA, Larsen SG, Warloe T, Stoldt S, Nesland JM, Suo ZH, Giercksky KE (2009)
Adenocarcinomas on the rise--does it influence survival from oesophageal cancer?
Scand J Surg, 98 (4), 214-20
DOI 10.1177/145749690909800404, PubMed 20218417

Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
Prostate, 68 (15), 1607-14
DOI 10.1002/pros.20826, PubMed 18655095

Wang Z, Tropè CG, Suo Z, Trøen G, Yang G, Nesland JM, Holm R (2008)
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
BMC Cancer, 8, 308
DOI 10.1186/1471-2407-8-308, PubMed 18950492

Goscinski MA, Suo ZH, Nesland JM, Flørenes VA, Giercksky KE (2008)
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines
APMIS, 116 (9), 823-31
DOI 10.1111/j.1600-0463.2008.01029.x, PubMed 19024603

Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson B, Risberg B (2008)
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
Diagn Cytopathol, 36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM (2008)
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination
Clin Cancer Res, 14 (8), 2341-50
DOI 10.1158/1078-0432.CCR-07-4214, PubMed 18413823

Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL (2008)
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827

Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE (2008)
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
Ultrastruct Pathol, 32 (3), 89-96
DOI 10.1080/01913120802034934, PubMed 18570153

Goscinski MA, Suo ZH, Nesland JM, Chen WT, Zakrzewska M, Wang J, Zhang S, Flørenes VA, Giercksky KE (2008)
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China
Oncology, 75 (1-2), 49-59
DOI 10.1159/000151741, PubMed 18787344

Bjerkehagen B, Smeland S, Walberg L, Skjeldal S, Hall KS, Nesland JM, Småstuen MC, Fosså SD, Saeter G (2008)
Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital
Acta Oncol, 47 (8), 1475-82
DOI 10.1080/02841860802047387, PubMed 18607853

Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388

Khouja MH, Baekelandt M, Nesland JM, Holm R (2007)
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma
Int J Gynecol Pathol, 26 (4), 418-25
DOI 10.1097/pgp.0b013e31804216a0, PubMed 17885492

Kleinberg L, Flørenes VA, Nesland JM, Davidson B (2007)
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
Am J Clin Pathol, 128 (3), 389-97
DOI 10.1309/E899BG1282M5D505, PubMed 17709312

Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE (2007)
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
Mol Cancer, 6, 45
DOI 10.1186/1476-4598-6-45, PubMed 17623056

Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J (2007)
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours
Oncogene, 26 (53), 7414-22
DOI 10.1038/sj.onc.1210553, PubMed 17546051

Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2007)
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 61 (1), 59-63
DOI 10.1136/jcp.2006.045864, PubMed 17468294

Zhang MZ, Qiao YH, Nesland JM, Trope C, Kennedy A, Chen WT, Suo ZH (2007)
Expression of seprase in effusions from patients with epithelial ovarian carcinoma
Chin Med J (Engl), 120 (8), 663-8
PubMed 17517181

Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
Int J Cancer, 120 (8), 1603-9
DOI 10.1002/ijc.22488, PubMed 17230512

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292

Cunderlíková B, Wahlqvist R, Berner A, Vasovic V, Warloe T, Nesland JM, Peng Q (2007)
Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples
Cytopathology, 18 (2), 87-95
DOI 10.1111/j.1365-2303.2007.00436.x, PubMed 17397493

Røtterud R, Fosså SD, Nesland JM (2007)
Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium
Histol Histopathol, 22 (4), 349-63
DOI 10.14670/HH-22.349, PubMed 17290345

Kleinberg L, Lie AK, Flørenes VA, Nesland JM, Davidson B (2007)
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
Hum Pathol, 38 (7), 986-994
DOI 10.1016/j.humpath.2006.12.013, PubMed 17350081

Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759

Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
Mol Cancer, 6, 2
DOI 10.1186/1476-4598-6-2, PubMed 17201907

Langseth H, Johansen BV, Nesland JM, Kjaerheim K (2007)
Asbestos fibers in ovarian tissue from Norwegian pulp and paper workers
Int J Gynecol Cancer, 17 (1), 44-9
DOI 10.1111/j.1525-1438.2006.00768.x, PubMed 17291230

Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z (2007)
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
Epigenetics, 2 (4), 237-43
DOI 10.4161/epi.2.4.5406, PubMed 18281782

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS (2007)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Breast Cancer Res, 9 (3), R30
DOI 10.1186/bcr1675, PubMed 17504517

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2006)
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 60 (10), 1086-91
DOI 10.1136/jcp.2006.041194, PubMed 17158642

Borgen E, Pantel K, Schlimok G, Müller P, Otte M, Renolen A, Ehnle S, Coith C, Nesland JM, Naume B (2006)
A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow
Cytometry B Clin Cytom, 70 (6), 400-9
DOI 10.1002/cyto.b.20114, PubMed 16924637

Furre IE, Møller MT, Shahzidi S, Nesland JM, Peng Q (2006)
Involvement of both caspase-dependent and -independent pathways in apoptotic induction by hexaminolevulinate-mediated photodynamic therapy in human lymphoma cells
Apoptosis, 11 (11), 2031-42
DOI 10.1007/s10495-006-0190-x, PubMed 17036199

Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT (2006)
Activation of EDTA-resistant gelatinases in malignant human tumors
Cancer Res, 66 (20), 9977-85
DOI 10.1158/0008-5472.CAN-06-1499, PubMed 17047060

Bukholm IR, Nesland JM, Bukholm G (2006)
Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours
Pathology, 38 (5), 403-7
DOI 10.1080/00313020600922520, PubMed 17008277

Steffensen IL, Schut HA, Nesland JM, Tanaka K, Alexander J (2006)
Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice
Mutat Res, 611 (1-2), 71-82
DOI 10.1016/j.mrgentox.2006.07.004, PubMed 16962818

Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL (2006)
Radiation-induced effects on gene expression: an in vivo study on breast cancer
Radiother Oncol, 80 (2), 230-5
DOI 10.1016/j.radonc.2006.07.007, PubMed 16890317

Knopp S, Nesland JM, Tropé C, Holm R (2006)
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
Am J Clin Pathol, 126 (2), 266-76
DOI 10.1309/e9e8y9wg5qe3lk29, PubMed 16891203

Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC (2006)
Metaplastic breast carcinomas are basal-like tumours
Histopathology, 49 (1), 10-21
DOI 10.1111/j.1365-2559.2006.02467.x, PubMed 16842242

Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H (2006)
Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells
Clin Cancer Res, 12 (13), 4055-61
DOI 10.1158/1078-0432.CCR-05-2482, PubMed 16818705

Bassarova AV, Nesland JM, Davidson B (2006)
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions
Am J Surg Pathol, 30 (7), 878-82
DOI 10.1097/01.pas.0000208280.29291.34, PubMed 16819331

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Int J Cancer, 118 (11), 2877-81
DOI 10.1002/ijc.21709, PubMed 16381016

Ji Z, Yang G, Vasovic V, Cunderlikova B, Suo Z, Nesland JM, Peng Q (2006)
Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines
J Photochem Photobiol B, 84 (3), 213-20
DOI 10.1016/j.jphotobiol.2006.03.006, PubMed 16709459

Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, Naume B (2006)
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer
Int J Cancer, 118 (8), 2013-9
DOI 10.1002/ijc.21576, PubMed 16287086

Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
DOI 10.1080/00313020600561526, PubMed 16680901

Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B (2006)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch, 449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284

Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006)
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Gynecol Oncol, 102 (1), 15-21
DOI 10.1016/j.ygyno.2005.11.034, PubMed 16499955

Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G, Nesland JM, Reich R (2006)
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma
Gynecol Oncol, 102 (3), 453-61
DOI 10.1016/j.ygyno.2006.01.034, PubMed 16494928

Ji Z, Yang G, Shahzidi S, Tkacz-Stachowska K, Suo Z, Nesland JM, Peng Q (2006)
Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy
Cancer Lett, 244 (2), 182-9
DOI 10.1016/j.canlet.2005.12.010, PubMed 16427735

Shahzidi S, Stokke T, Soltani H, Nesland JM, Peng Q (2006)
Induction of apoptosis by hexaminolevulinate-mediated photodynamic therapy in human colon carcinoma cell line 320DM
J Environ Pathol Toxicol Oncol, 25 (1-2), 159-71
DOI 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.90, PubMed 16566715

Lazarova P, Wu Q, Kvalheim G, Suo Z, Haakenstad KW, Metodiev K, Nesland JM (2006)
Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood
Int J Immunopathol Pharmacol, 19 (1), 49-56
PubMed 16569339

Godal A, Nilsen NO, Klaveness J, Branden JE, Nesland JM, Peng Q (2006)
New derivatives of 5-aminolevulinic acid for photodynamic therapy: chemical synthesis and porphyrin production in in vitro and in vivo biological systems
J Environ Pathol Toxicol Oncol, 25 (1-2), 109-26
DOI 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.60, PubMed 16566712

Furre IE, Shahzidi S, Luksiene Z, Møller MT, Borgen E, Morgan J, Tkacz-Stachowska K, Nesland JM, Peng Q (2005)
Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells
Cancer Res, 65 (23), 11051-60
DOI 10.1158/0008-5472.CAN-05-0510, PubMed 16322255

Kringen P, Bergamaschi A, Due EU, Wang Y, Tagliabue E, Nesland JM, Nehman A, Tönisson N, Børresen-Dale AL (2005)
Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas
Biotechniques, 39 (5), 755-61
DOI 10.2144/000112000, PubMed 16312222

Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B (2005)
Angiogenic molecule expression is downregulated in effusions from breast cancer patients
Breast Cancer Res Treat, 94 (1), 71-80
DOI 10.1007/s10549-005-7328-3, PubMed 16142438

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746

Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005)
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Gynecol Oncol, 99 (2), 278-86
DOI 10.1016/j.ygyno.2005.06.036, PubMed 16061279

Knopp S, Holm R, Tropé C, Nesland JM (2005)
Occult lymph node metastases in early stage vulvar carcinoma patients
Gynecol Oncol, 99 (2), 383-7
DOI 10.1016/j.ygyno.2005.06.023, PubMed 16051338

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759

Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
J Pathol, 206 (3), 312-9
DOI 10.1002/path.1777, PubMed 15892171

Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, Torlakovic E (2005)
Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53
Int J Surg Pathol, 13 (3), 239-46
DOI 10.1177/106689690501300302, PubMed 16086078

Bassarova AV, Torlakovic E, Sedloev T, Hristova SL, Trifonov DV, Nesland JM (2005)
Simultaneous bilateral breast carcinoma: Histopathological characteristics and CD44/catenin-cadherin profile
Histol Histopathol, 20 (3), 791-9
DOI 10.14670/HH-20.791, PubMed 15944928

Skotheim RI, Lind GE, Monni O, Nesland JM, Abeler VM, Fosså SD, Duale N, Brunborg G, Kallioniemi O, Andrews PW, Lothe RA (2005)
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development
Cancer Res, 65 (13), 5588-98
DOI 10.1158/0008-5472.CAN-05-0153, PubMed 15994931

Bondi J, Bukholm G, Nesland JM, Bakka A, Bukholm IR (2005)
An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients
Int J Colorectal Dis, 21 (3), 231-7
DOI 10.1007/s00384-005-0762-1, PubMed 15937692

Røtterud R, Nesland JM, Berner A, Fosså SD (2005)
Expression of the epidermal growth factor receptor family in normal and malignant urothelium
BJU Int, 95 (9), 1344-50
DOI 10.1111/j.1464-410X.2005.05497.x, PubMed 15892828

Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R (2005)
Cyclins D1, D3, E, and A in vulvar carcinoma patients
Gynecol Oncol, 97 (3), 733-9
DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358

Torlakovic G, Torlakovic E, Skovlund E, Nesland JM, Reith A, Danielsen HE (2005)
Volume-related sequence of tumor distribution pattern in prostate carcinoma: importance of posterior midline crossover in predicting tumor volume, extracapsular extension, and seminal vesicle invasion
Croat Med J, 46 (3), 429-35
PubMed 15861523

Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR (2005)
Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome
J Clin Pathol, 58 (5), 509-14
DOI 10.1136/jcp.2004.020347, PubMed 15858123

Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005)
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
Cancer, 103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334

Kildal W, Risberg B, Abeler VM, Kristensen GB, Sudbø J, Nesland JM, Danielsen HE (2005)
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
Eur J Cancer, 41 (8), 1127-34
DOI 10.1016/j.ejca.2005.01.022, PubMed 15911235

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J (2005)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Nature, 434 (7035), 864-70
DOI 10.1038/nature03482, PubMed 15829956

Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005)
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177

Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM, Suo Z (2005)
Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma
Anticancer Res, 25 (4), 2943-50
PubMed 16080548

Shi HR, Wu QH, Suo ZH, Nesland JM (2005)
[Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer]
Ai Zheng, 24 (1), 7-11
PubMed 15642192

Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC (2005)
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
Breast Cancer Res, 7 (6), R1028-35
DOI 10.1186/bcr1341, PubMed 16280056

Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943

Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Flørenes VA (2004)
Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis
Mod Pathol, 17 (11), 1400-6
DOI 10.1038/modpathol.3800206, PubMed 15205685

Li HX, Zh S, Zhang YH, Risberg B, Karlsson MG, Nesland JM (2004)
[Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis]
Zhonghua Zhong Liu Za Zhi, 26 (11), 669-72
PubMed 15777505

Suo Z, Daehli KU, Lindboe CF, Borgen E, Bassarova A, Nesland JM (2004)
Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients
Int J Surg Pathol, 12 (4), 311-8
DOI 10.1177/106689690401200404, PubMed 15494857

Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R (2004)
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Gynecol Oncol, 95 (1), 37-45
DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108

Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE (2004)
CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression
Mod Pathol, 17 (10), 1251-8
DOI 10.1038/modpathol.3800174, PubMed 15205682

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004)
Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome
Clin Cancer Res, 10 (16), 5342-8
DOI 10.1158/1078-0432.CCR-04-0245, PubMed 15328170

Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol, 17 (8), 990-7
DOI 10.1038/modpathol.3800151, PubMed 15133476

Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004)
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
Gynecol Oncol, 94 (2), 312-9
DOI 10.1016/j.ygyno.2004.05.019, PubMed 15297167

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786

Flørenes VA, Skrede M, Jørgensen K, Nesland JM (2004)
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res, 14 (3), 173-81
DOI 10.1097/01.cmr.0000129576.49313.26, PubMed 15179185

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004)
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells
Clin Cancer Res, 10 (9), 3091-7
DOI 10.1158/1078-0432.ccr-03-0373, PubMed 15131048

Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R (2004)
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
Gynecol Oncol, 93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972

Bassarova A, Nesland JM, Sedloev T, Danielsen H, Christova S (2004)
Pilomatrix carcinoma with lymph node metastases
J Cutan Pathol, 31 (4), 330-5
DOI 10.1111/j.0303-6987.2004.0178.x, PubMed 15005691

Zhao H, Langerød A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Børresen-Dale AL, Jeffrey SS (2004)
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast
Mol Biol Cell, 15 (6), 2523-36
DOI 10.1091/mbc.e03-11-0786, PubMed 15034139

Diep CB, Teixeira MR, Thorstensen L, Wiig JN, Eknaes M, Nesland JM, Giercksky KE, Johansson B, Lothe RA (2004)
Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients
Mol Cancer, 3, 6
DOI 10.1186/1476-4598-3-6, PubMed 14977426

Hernes E, Fosså SD, Berner A, Otnes B, Nesland JM (2004)
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
Br J Cancer, 90 (2), 449-54
DOI 10.1038/sj.bjc.6601536, PubMed 14735192

Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM (2004)
Expression of Ephb2 and Ephb4 in breast carcinoma
Pathol Oncol Res, 10 (1), 26-33
DOI 10.1007/BF02893405, PubMed 15029258

Lindboe CF, Matre J, Nesland JM (2004)
Adenoma of the esophagus with intracytoplasmic mucoid bodies
APMIS, 112 (1), 29-33
DOI 10.1111/j.1600-0463.2004.apm1120105.x, PubMed 14961971

Lazarova P, Lijun M, Hammerstad H, Nesland J, Gaudernack G, Kvalheim G (2004)
Experimental attempt to introduce a vaccine therapy by using DC-developed from CD34+cells
NATO SCI SER I LIFE, 361, 134

Li H, Suo Z, Zhang Y, Risberg B, Karlsson MG, Villman K, Nesland JM (2004)
The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas
Histol Histopathol, 19 (1), 129-36
DOI 10.14670/HH-19.129, PubMed 14702180

Naume B, Borgen E, Tøssvik S, Pavlak N, Oates D, Nesland JM (2004)
Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method
Cytotherapy, 6 (3), 244-52
DOI 10.1080/14653240410006086, PubMed 15203981

Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z (2004)
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
Pathol Oncol Res, 10 (4), 212-8
DOI 10.1007/BF03033763, PubMed 15619642

Suo Z, Karbovo E, Trope CG, Metodiev K, Nesland JM (2004)
Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study
Ultrastruct Pathol, 28 (3), 141-7
DOI 10.1080/01913120490475716, PubMed 15471427

Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM (2004)
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma
Breast Cancer Res Treat, 83 (2), 119-28
DOI 10.1023/B:BREA.0000010704.17479.8a, PubMed 14997042

Bondi J, Bukholm G, Nesland JM, Bukholm IR (2004)
Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas
APMIS, 112 (1), 49-56
DOI 10.1111/j.1600-0463.2004.apm1120109.x, PubMed 14961975

Peng Q, Nesland JM (2004)
Effects of photodynamic therapy on tumor stroma
Ultrastruct Pathol, 28 (5-6), 333-40
DOI 10.1080/01913120490515586, PubMed 15764581

Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D, Torlakovic E (2004)
Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma
Am J Clin Pathol, 121 (1), 34-42
DOI 10.1309/TNKL-7GDC-66R9-WPV5, PubMed 14750238

Reed W, Bøhler PJ, Sandstad B, Nesland JM (2004)
Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up
Breast J, 10 (3), 174-80
DOI 10.1111/j.1075-122X.2004.21328.x, PubMed 15125740

Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA (2003)
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome
J Clin Oncol, 21 (24), 4586-91
DOI 10.1200/JCO.2003.07.067, PubMed 14673046

Skotheim RI, Korkmaz KS, Klokk TI, Abeler VM, Korkmaz CG, Nesland JM, Fosså SD, Lothe RA, Saatcioglu F (2003)
NKX3.1 expression is lost in testicular germ cell tumors
Am J Pathol, 163 (6), 2149-54
DOI 10.1016/S0002-9440(10)63571-7, PubMed 14633588

Bukholm IR, Bondi J, Wiik P, Nesland JM, Andersen SN, Bakka A, Bukholm G (2003)
Presence of isolated tumour cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer
Eur J Surg Oncol, 29 (10), 862-6
DOI 10.1016/j.ejso.2003.09.007, PubMed 14624779

Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, de Gouveia Brazao CA, Weber RF, Kirkels WJ, van Dijk T, von Lindern M, Valk P, Lajos G, Olah E, Nesland JM, Fosså SD, Oosterhuis JW (2003)
Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors
Cancer Res, 63 (22), 7674-8
PubMed 14633689

Sudbø J, Reith A, Flørenes VA, Nesland JM, Ristimäki A, Bryne M (2003)
COX-2 expression in striated muscle under physiological conditions
Oral Dis, 9 (6), 313-6
DOI 10.1034/j.1601-0825.2003.00957.x, PubMed 14629333

Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003)
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
Gynecol Oncol, 91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003)
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer
J Clin Oncol, 21 (18), 3469-78
DOI 10.1200/JCO.2003.02.009, PubMed 12972522

Fosså SD, Aass N, Heilo A, Daugaard G, E Skakkebaek N, Stenwig AE, Nesland JM, Looijenga LH, Oosterhuis JW (2003)
Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy
Ann Oncol, 14 (9), 1412-8
DOI 10.1093/annonc/mdg373, PubMed 12954581

Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
Clin Cancer Res, 9 (9), 3383-8
PubMed 12960126

Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM (2003)
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
J Pathol, 200 (5), 589-95
DOI 10.1002/path.1381, PubMed 12898594

Bukholm IR, Husdal A, Nesland JM, Langerød A, Bukholm G (2003)
Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time
Breast Cancer Res Treat, 80 (2), 199-206
DOI 10.1023/A:1024527220362, PubMed 12908823

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393

Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM (2003)
Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas
Histopathology, 42 (6), 546-54
DOI 10.1046/j.1365-2559.2003.01622.x, PubMed 12786890

Reed W, Hannisdal E, Skovlund E, Thoresen S, Lilleng P, Nesland JM (2003)
Pregnancy and breast cancer: a population-based study
Virchows Arch, 443 (1), 44-50
DOI 10.1007/s00428-003-0817-z, PubMed 12756565

Bukholm IR, Bukholm G, Holm R, Nesland JM (2003)
Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas
J Clin Pathol, 56 (5), 368-73
DOI 10.1136/jcp.56.5.368, PubMed 12719458

Reed W, Sandstad B, Holm R, Nesland JM (2003)
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators
Int J Surg Pathol, 11 (2), 65-74
DOI 10.1177/106689690301100201, PubMed 12754622

Suo Z, Nesland JM (2003)
Electron microscopy in diagnosis of spindle cell tumors
Semin Diagn Pathol, 20 (1), 5-12
DOI 10.1053/sdia.2003.50006, PubMed 12693671

Diep CB, Parada LA, Teixeira MR, Eknaes M, Nesland JM, Johansson B, Lothe RA (2003)
Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis
Genes Chromosomes Cancer, 36 (2), 189-97
DOI 10.1002/gcc.10162, PubMed 12508247

Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM (2003)
Morphologic reappraisal of serrated colorectal polyps
Am J Surg Pathol, 27 (1), 65-81
DOI 10.1097/00000478-200301000-00008, PubMed 12502929

Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R (2003)
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O (2003)
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717

Skotheim RI, Abeler VM, Nesland JM, Fosså SD, Holm R, Wagner U, Flørenes VA, Aass N, Kallioniemi OP, Lothe RA (2003)
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
Neoplasia, 5 (5), 397-404
DOI 10.1016/s1476-5586(03)80042-8, PubMed 14670177

Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
Int J Cancer, 103 (1), 91-6
DOI 10.1002/ijc.10780, PubMed 12455058

Wu Q, Shi H, Suo Z, Nesland JM (2003)
5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas
Ultrastruct Pathol, 27 (6), 417-22
DOI 10.1080/01913120390250329, PubMed 14660280

Pedersen KB, Nesland JM, Fodstad Ø, Maelandsmo GM (2002)
Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies
Br J Cancer, 87 (11), 1281-6
DOI 10.1038/sj.bjc.6600624, PubMed 12439718

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Johannessen HO, Dale E, Hellebust TP, Olsen DR, Nesland JM, Giercksky KE (2002)
Modeling volume effects of experimental brachytherapy in the rat rectum: uncovering the limitations of a radiobiologic concept
Int J Radiat Oncol Biol Phys, 53 (4), 1014-22
DOI 10.1016/s0360-3016(02)02835-3, PubMed 12095571

Karbova E, Davidson B, Metodiev K, Tropé CG, Nesland JM (2002)
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
Int J Surg Pathol, 10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570

Lopes JM, Nesland JM, Reis-Filho JS, Holm R (2002)
Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin
Histopathology, 40 (5), 464-71
DOI 10.1046/j.1365-2559.2002.01371.x, PubMed 12010367

Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, Nesland JM (2002)
The expression of EGFR family ligands in breast carcinomas
Int J Surg Pathol, 10 (2), 91-9
DOI 10.1177/106689690201000202, PubMed 12075402

Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
Oncogene, 21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409

Bukholm IR, Bukholm G, Nesland JM (2002)
Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas
APMIS, 110 (3), 214-20
DOI 10.1034/j.1600-0463.2002.100303.x, PubMed 12076274

Lorico A, Nesland J, Emilsen E, Fodstad O, Rappa G (2002)
Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice
Toxicology, 171 (2-3), 201-5
DOI 10.1016/s0300-483x(01)00584-4, PubMed 11836025

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R (2002)
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
Mol Cell Endocrinol, 187 (1-2), 39-45
DOI 10.1016/s0303-7207(01)00709-2, PubMed 11988310

Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219

Kraggerud SM, Aman P, Holm R, Stenwig AE, Fosså SD, Nesland JM, Lothe RA (2002)
Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis
Cancer Res, 62 (2), 512-7
PubMed 11809703

Eyden B, Banerjee SS, Nesland JM (2002)
Amphicrine carcinoma of breast with giant granules: an immunohistochemical, histochemical and ultrastructural study
J Submicrosc Cytol Pathol, 34 (1), 27-36
PubMed 11989854

Yang H, Berner A, Mei Q, Giercksky KE, Warloe T, Yang G, Cui J, Suo Z, Zhang S, Nesland JM (2002)
Cytologic screening for esophageal cancer in a high-risk population in Anyang County, China
Acta Cytol, 46 (3), 445-52
DOI 10.1159/000326859, PubMed 12040635

Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077

Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM (2002)
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
J Pathol, 196 (1), 17-25
DOI 10.1002/path.1003, PubMed 11748637

Scheistrøen M, Nesland JM, Tropé C (2002)
Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
Eur J Gynaecol Oncol, 23 (2), 93-103
PubMed 12013120

Bassarova AV, Sedloev T, Christova SL, Trifonov DY, Nesland JM (2002)
Invasive lobular carcinoma in a hypoplastic breast
Ultrastruct Pathol, 26 (6), 411-4
DOI 10.1080/01913120290104728, PubMed 12537766

Naume B, Borgen E, Kvalheim G, Kåresen R, Qvist H, Sauer T, Kumar T, Nesland JM (2001)
Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics
Clin Cancer Res, 7 (12), 4122-9
PubMed 11751511

Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001)
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol, 195 (5), 530-6
DOI 10.1002/path.1007, PubMed 11745687

Thorstensen L, Qvist H, Nesland JM, Giercksky KE, Lothe RA (2001)
Identification of two potential suppressor gene regions on chromosome arm 14q that are commonly lost in advanced colorectal carcinomas
Scand J Gastroenterol, 36 (12), 1327-31
DOI 10.1080/003655201317097209, PubMed 11761025

Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001)
Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
Clin Cancer Res, 7 (12), 4073-9
PubMed 11751504

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R (2001)
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
Am J Surg Pathol, 25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079

Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863

Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G (2001)
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
Proc Natl Acad Sci U S A, 98 (23), 13255-60
DOI 10.1073/pnas.231326898, PubMed 11687624

Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
Oncogene, 20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967

Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE (2001)
Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate
J Photochem Photobiol B, 62 (3), 140-5
DOI 10.1016/s1011-1344(01)00173-7, PubMed 11566277

Borgen E, Naume B, Nesland JM, Nowels KW, Pavlak N, Ravkin I, Goldbard S (2001)
Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples
Cytometry, 46 (4), 215-21
DOI 10.1002/cyto.1130, PubMed 11514954

Luksiene Z, Eggen I, Moan J, Nesland JM, Peng Q (2001)
Evaluation of protoporphyrin IX production, phototoxicity and cell death pathway induced by hexylester of 5-aminolevulinic acid in Reh and HPB-ALL cells
Cancer Lett, 169 (1), 33-9
DOI 10.1016/s0304-3835(01)00559-6, PubMed 11410323

Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM (2001)
Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts
Cancer Res, 61 (15), 5824-32
PubMed 11479222

Bukholm IR, Bukholm G, Nesland JM (2001)
Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas
Int J Cancer, 93 (2), 283-7
DOI 10.1002/ijc.1311, PubMed 11410878

Suo Z, Yang H, Mei Q, Skovlund E, Cui J, Nesland JM (2001)
Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study
Int J Surg Pathol, 9 (3), 177-87
DOI 10.1177/106689690100900303, PubMed 11584314

Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM (2001)
Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas
Virchows Arch, 439 (1), 62-9
DOI 10.1007/s004280000392, PubMed 11499842

Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, Reich R (2001)
Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study
Gynecol Oncol, 81 (2), 166-71
DOI 10.1006/gyno.2001.6156, PubMed 11330944

Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899

Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM (2001)
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
Clin Cancer Res, 7 (3), 551-7
PubMed 11297247

Berner HS, Nesland JM (2001)
Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast
Breast Cancer Res Treat, 65 (1), 23-9
DOI 10.1023/a:1006417412046, PubMed 11245336

Suo Z, Bjaamer A, Ottestad L, Nesland JM (2001)
Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast
Ultrastruct Pathol, 25 (5), 349-56
DOI 10.1080/019131201317101216, PubMed 11758715

Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863

Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A (2000)
E-Cadherin complex protein expression and survival in ovarian carcinoma
Gynecol Oncol, 79 (3), 362-71
DOI 10.1006/gyno.2000.5964, PubMed 11104606

Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490

Høie J, Heimdal K, Nesland JM, Børmer O (2000)
[Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers]
Tidsskr Nor Laegeforen, 120 (27), 3249-52
PubMed 11187163

Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000)
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res, 6 (9), 3614-20
PubMed 10999753

Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M (2000)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
DOI 10.1053/hupa.2000.9776, PubMed 11014575

Knudsen P, Ryther AJ, Nesheim JA, Abeler VM, Nesland JM, Danielsen HE (2000)
[Telepathology at the Norwegian Radium Hospital]
Tidsskr Nor Laegeforen, 120 (18), 2170-3
PubMed 11006741

Anvar MD, Khiabani HZ, Nesland JM, Stranden E, Kroese AJ (2000)
Vascular and stromal features in the skin of the lower limb in patients with chronic critical limb ischaemia (CLI) and oedema
Eur J Vasc Endovasc Surg, 20 (2), 125-31
DOI 10.1053/ejvs.2000.1142, PubMed 10942683

Risberg B, Davidson B, Dong HP, Nesland JM, Berner A (2000)
Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings
J Clin Pathol, 53 (7), 513-7
DOI 10.1136/jcp.53.7.513, PubMed 10961174

Berner HS, Davidson B, Berner A, Risberg B, Nesland JM (2000)
Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions
Virchows Arch, 436 (4), 330-5
DOI 10.1007/s004280050455, PubMed 10834535

Davidson B, Gotlieb WH, Ben-Baruch G, Kopolovic J, Goldberg I, Nesland JM, Berner A, Bjåmer A, Bryne M (2000)
Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study
Gynecol Oncol, 77 (1), 35-43
DOI 10.1006/gyno.1999.5708, PubMed 10739688

Bukholm IK, Nesland JM (2000)
Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas
Virchows Arch, 436 (3), 224-8
DOI 10.1007/s004280050034, PubMed 10782880

De Jonge ET, Lindeque BG, Burger W, Nesland JM, Holm R (2000)
Predicting response to neoadjuvant chemotherapy in patients with cervical carcinoma: can we do without any longer?
Int J Gynecol Cancer, 10 (2), 137-142
DOI 10.1046/j.1525-1438.2000.00022.x, PubMed 11240665

Thorstensen L, Qvist H, Heim S, Liefers GJ, Nesland JM, Giercksky KE, Lothe RA (2000)
Evaluation of 1p losses in primary carcinomas, local recurrences and peripheral metastases from colorectal cancer patients
Neoplasia, 2 (6), 514-22
DOI 10.1038/sj.neo.7900111, PubMed 11228544

Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398

Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000)
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
Clin Exp Metastasis, 18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996

Davidson B, Goldberg I, Kopolovic J, Gotlieb WH, Givant-Horwitz V, Nesland JM, Berner A, Ben-Baruch G, Bryne M, Reich R (2000)
Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study
Clin Exp Metastasis, 18 (6), 501-7
DOI 10.1023/a:1011858225144, PubMed 11592307

Bironaite D, Nesland JM, Dalen H, Risberg B, Bryne M (2000)
N-Glycans influence the in vitro adhesive and invasive behaviour of three metastatic cell lines
Tumour Biol, 21 (3), 165-75
DOI 10.1159/000030123, PubMed 10754467

Suo Z, Nesland JM (2000)
Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features
Ultrastruct Pathol, 24 (6), 371-81
DOI 10.1080/019131200750060032, PubMed 11206334

Bukholm IK, Nesland JM, Børresen-Dale AL (2000)
Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]
J Pathol, 190 (1), 15-9
DOI 10.1002/(SICI)1096-9896(200001)190:1<15::AID-PATH489>3.0.CO;2-L, PubMed 10640987

van Slooten HJ, van De Vijver MJ, Borresen AL, Eyfjörd JE, Valgardsdóttir R, Scherneck S, Nesland JM, Devilee P, Cornelisse CJ, van Dierendonck JH (1999)
Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma
J Pathol, 189 (4), 504-13
DOI 10.1002/(SICI)1096-9896(199912)189:4<504::AID-PATH483>3.0.CO;2-A, PubMed 10629550

Bjerkehagen B, Dietrich C, Reed W, Micci F, Saeter G, Berner A, Nesland JM, Heim S (1999)
Extraskeletal myxoid chondrosarcoma: multimodal diagnosis and identification of a new cytogenetic subgroup characterized by t(9;17)(q22;q11)
Virchows Arch, 435 (5), 524-30
DOI 10.1007/s004280050437, PubMed 10592057

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer
Ann Oncol, 10 (11), 1335-41
DOI 10.1023/a:1008352502465, PubMed 10631462

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study
Clin Cancer Res, 5 (10), 2848-53
PubMed 10537352

Hennig EM, Di Lonardo A, Venuti A, Holm R, Marcante ML, Nesland JM (1999)
HPV 16 in multiple neoplastic lesions in women with CIN III
J Exp Clin Cancer Res, 18 (3), 369-77
PubMed 10606184

Reed W, Flørems VA, Holm R, Hannisdal E, Nesland JM (1999)
Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients
Virchows Arch, 435 (2), 116-24
DOI 10.1007/s004280050408, PubMed 10599310

Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R (1999)
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer
J Clin Oncol, 17 (7), 2061
DOI 10.1200/JCO.1999.17.7.2061, PubMed 10561259

De Jonge ET, Viljoen E, Lindeque BG, Amant F, Nesland JM, Holm R (1999)
The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy
Int J Gynecol Cancer, 9 (3), 198-205
DOI 10.1046/j.1525-1438.1999.99019.x, PubMed 11240767

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R (1999)
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
J Pathol, 187 (5), 556-62
DOI 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y, PubMed 10398121

Hennig EM, Nesland JM, Di Lonardo A, Venuti A (1999)
Multiple primary cancers and HPV infection: are they related?
J Exp Clin Cancer Res, 18 (1), 53-4
PubMed 10374677

Scheistrøen M, Tropé C, Pettersen EO, Nesland JM (1999)
p53 protein expression in squamous cell carcinoma of the vulva
Cancer, 85 (5), 1133-8
DOI 10.1002/(SICI)1097-0142(19990301)85:5<1133::AID-CNCR17>3.0.CO;2-T, PubMed 10091798

Nesland JM (1999)
[Molecular genetic mechanisms and hereditary disease]
Tidsskr Nor Laegeforen, 119 (6), 779
PubMed 10101934

Jensen P, Nesland JM (1999)
[Research publication, the faculties, the Tidsskrift]
Tidsskr Nor Laegeforen, 119 (4), 489
PubMed 10081369

Noodt BB, Berg K, Stokke T, Peng Q, Nesland JM (1999)
Different apoptotic pathways are induced from various intracellular sites by tetraphenylporphyrins and light
Br J Cancer, 79 (1), 72-81
DOI 10.1038/sj.bjc.6690014, PubMed 10408696

Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM (1999)
Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III)
Breast Cancer Res Treat, 53 (2), 121-35
DOI 10.1023/a:1006162609420, PubMed 10326789

Baekelandt M, Kristensen GB, Tropé CG, Nesland JM, Holm R (1999)
Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer
Anticancer Res, 19 (5C), 4469-74
PubMed 10650794

Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K (1999)
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells
Cytotherapy, 1 (5), 377-88
DOI 10.1080/0032472031000141283, PubMed 20426539

Raabe NK, Sauer T, Erichsen A, Nesland JM, Fossaa SD (1999)
Breast cancer in the contralateral breast: incidence and histopathology after unilateral radical treatment of the first breast cancer
Oncol Rep, 6 (5), 1001-7
DOI 10.3892/or.6.5.1001, PubMed 10425294

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R (1999)
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
Clin Exp Metastasis, 17 (10), 799-808
DOI 10.1023/a:1006723011835, PubMed 11089877

Hennig EM, Suo Z, Karlsen F, Holm R, Thoresen S, Nesland JM (1999)
HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III)
Acta Oncol, 38 (5), 639-47
DOI 10.1080/028418699431258, PubMed 10427955

Hennig EM, Kvinnsland S, Holm R, Nesland JM (1999)
Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas
Acta Oncol, 38 (7), 931-8
DOI 10.1080/028418699432617, PubMed 10606422

Suo Z, Emilsen E, Tveit KM, Nesland JM (1998)
Type 1 protein tyrosine kinases in benign and malignant breast lesions
Histopathology, 33 (6), 514-21
DOI 10.1046/j.1365-2559.1998.00498.x, PubMed 9870145

Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, Ravnås G, Qvist H, Kåresen R, Kvalheim G (1998)
Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
Int J Cancer, 78 (5), 556-60
DOI 10.1002/(sici)1097-0215(19981123)78:5<556::aid-ijc5>3.0.co;2-g, PubMed 9808522

Nedelcheva Kristensen V, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, Børresen-Dale AL (1998)
Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients
Pharmacogenetics, 8 (5), 441-7
DOI 10.1097/00008571-199810000-00009, PubMed 9825836

Bukholm IK, Berner JM, Nesland JM, Børresen-Dale AL (1998)
Expression of cyclin Ds in relation to p53 status in human breast carcinomas
Virchows Arch, 433 (3), 223-8
DOI 10.1007/s004280050240, PubMed 9769125

Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B (1998)
Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
J Pathol, 185 (4), 427-34
DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7, PubMed 9828843

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL (1998)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma
J Pathol, 185 (3), 262-6
DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y, PubMed 9771479

Nordal RR, Kristensen GB, Stenwig AE, Tropé CG, Nesland JM (1998)
Immunohistochemical analysis of p53 protein in uterine sarcomas
Gynecol Oncol, 70 (1), 45-8
DOI 10.1006/gyno.1998.5034, PubMed 9698472

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R (1998)
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
Am J Pathol, 153 (1), 305-12
DOI 10.1016/S0002-9440(10)65572-1, PubMed 9665492

Børresen-Dale AL, Lothe RA, Nesland JM (1998)
[Molecular biology. Basis for increased understanding of diseases and improved diagnostics]
Tidsskr Nor Laegeforen, 118 (11), 1681
PubMed 9621751

Noodt BB, Rodal GH, Wainwright M, Peng Q, Horobin R, Nesland JM, Berg K (1998)
Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells
Int J Cancer, 75 (6), 941-8
DOI 10.1002/(sici)1097-0215(19980316)75:6<941::aid-ijc18>3.0.co;2-5, PubMed 9506541

Lopes JM, Hannisdal E, Bjerkehagen B, Bruland OS, Danielsen HE, Pettersen EO, Sobrinho-Simões M, Nesland JM (1998)
Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers
Anal Cell Pathol, 16 (1), 45-62
DOI 10.1155/1998/545906, PubMed 9584899

Bryne M, Boysen M, Alfsen CG, Abeler VM, Sudbø J, Nesland JM, Kristensen GB, Piffko J, Bankfalvi A (1998)
The invasive front of carcinomas. The most important area for tumour prognosis?
Anticancer Res, 18 (6B), 4757-64
PubMed 9891553

Kareem BN, Karlsen F, Holm R, Hennig EM, Suo Z, Emilsen E, Hellesylt E, Nesland JM (1997)
A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues
J Pathol, 183 (4), 486-93
DOI 10.1002/(SICI)1096-9896(199712)183:4<486::AID-PATH945>3.0.CO;2-D, PubMed 9496267

Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG (1997)
An evaluation of prognostic factors in uterine carcinosarcoma
Gynecol Oncol, 67 (3), 316-21
DOI 10.1006/gyno.1997.4875, PubMed 9441781

Giercksky HE, Thorstensen L, Qvist H, Nesland JM, Lothe RA (1997)
Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases
Diagn Mol Pathol, 6 (6), 318-25
DOI 10.1097/00019606-199712000-00003, PubMed 9559291

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL (1997)
Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas
Virchows Arch, 431 (5), 317-21
DOI 10.1007/s004280050105, PubMed 9463572

Fonseca E, Nesland JM, Sobrinho-Simões M (1997)
Expression of stratified epithelial-type cytokeratins in hyalinizing trabecular adenomas supports their relationship with papillary carcinomas of the thyroid
Histopathology, 31 (4), 330-5
DOI 10.1046/j.1365-2559.1997.2720878.x, PubMed 9363448

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen-Dale AL (1997)
Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53
Int J Cancer, 73 (1), 38-41
DOI 10.1002/(sici)1097-0215(19970926)73:1<38::aid-ijc7>3.0.co;2-2, PubMed 9334807

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
Clin Cancer Res, 3 (9), 1623-8
PubMed 9815852

Helland A, Børresen-Dale AL, Peltomäki P, Hektoen M, Kristensen GB, Nesland JM, de la Chapelle A, Lothe RA (1997)
Microsatellite instability in cervical and endometrial carcinomas
Int J Cancer, 70 (5), 499-501
DOI 10.1002/(sici)1097-0215(19970304)70:5<499::aid-ijc1>3.0.co;2-t, PubMed 9052745

Laake K, Odegård A, Andersen TI, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y, Børresen-Dale AL (1997)
Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM
Genes Chromosomes Cancer, 18 (3), 175-80
DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.3.CO;2-R, PubMed 9071570

Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M (1997)
Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins
Virchows Arch, 430 (3), 239-45
DOI 10.1007/BF01324808, PubMed 9099982

Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen AL (1997)
Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas
J Pathol, 181 (2), 140-5
DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A, PubMed 9120716

Scheistrøen M, Tropé C, Kaern J, Pettersen EO, Alfsen GC, Nesland JM (1997)
DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva
Gynecol Oncol, 64 (1), 88-92
DOI 10.1006/gyno.1996.4517, PubMed 8995553

Holm R, Flørenes VA, Erikstein B, Nesland JM (1997)
Expression of stromelysin-3 in medullary carcinoma of the breast
Anticancer Res, 17 (5B), 3725-7
PubMed 9427769

Thorstensen L, Qvist H, Nesland JM, Giercksky KE, Lothe RA (1996)
Allelotype profiles of local recurrences and distant metastases from colorectal-cancer patients
Int J Cancer, 69 (6), 452-6
DOI 10.1002/(SICI)1097-0215(19961220)69:6<452::AID-IJC6>3.0.CO;2-3, PubMed 8980246

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
Tidsskr Nor Laegeforen, 116 (21), 2542-6
PubMed 8928121

Noodt BB, Berg K, Stokke T, Peng Q, Nesland JM (1996)
Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX
Br J Cancer, 74 (1), 22-9
DOI 10.1038/bjc.1996.310, PubMed 8679453

Lundblad R, Nesland JM, Giercksky KE (1996)
Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats
Crit Care Med, 24 (5), 820-6
DOI 10.1097/00003246-199605000-00016, PubMed 8706460

Chitemerere M, Andersen TI, Holm R, Karlsen F, Børresen AL, Nesland JM (1996)
TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast
Breast Cancer Res Treat, 41 (2), 103-9
DOI 10.1007/BF01807155, PubMed 8944328

Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, Giercksky KE (1995)
Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma
Photochem Photobiol, 62 (5), 906-13
DOI 10.1111/j.1751-1097.1995.tb09154.x, PubMed 8570730

Lothe RA, Peltomäki P, Tommerup N, Fosså SD, Stenwig AE, Børresen AL, Nesland JM (1995)
Molecular genetic changes in human male germ cell tumors
Lab Invest, 73 (5), 606-14
PubMed 7474934

Nilsson A, Farrants AK, Nesland JM, Finstad HS, Pedersen JI (1995)
Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids
Eur J Cell Biol, 67 (4), 379-85
PubMed 8521878

Berner A, Geitvik G, Karlsen F, Fosså SD, Nesland JM, Børresen AL (1995)
TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue
J Pathol, 176 (3), 299-308
DOI 10.1002/path.1711760312, PubMed 7674092

Skomedal H, Kristensen G, Helland A, Nesland JM, Kooi S, Børresen AL, Holm R (1995)
TP53 gene mutations and protein accumulation in primary vaginal carcinomas
Br J Cancer, 72 (1), 129-33
DOI 10.1038/bjc.1995.288, PubMed 7599041

Peng Q, Moan J, Ma LW, Nesland JM (1995)
Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma
Cancer Res, 55 (12), 2620-6
PubMed 7780978

Dunsaed CB, Dornish JM, Aastveit TE, Nesland JM, Pettersen EO (1995)
Growth inhibition of human tumor xenografts in nude mice by treatment with the antitumor agent 4,6-benzylidene-d1-D-glucose (P-1013)
Anticancer Drugs, 6 (3), 456-64
DOI 10.1097/00001813-199506000-00015, PubMed 7670145

Helseth A, Haug E, Nesland JM, Siegal GP, Fodstad O, Bautch VL (1995)
Endocrine and metabolic characteristics of polyoma large T transgenic mice that develop ACTH-producing pituitary tumors
J Neurosurg, 82 (5), 879-85
DOI 10.3171/jns.1995.82.5.0879, PubMed 7714615

Holm R, Høie J, Kaalhus O, Nesland JM (1995)
Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinomas of the thyroid gland
Virchows Arch, 427 (3), 289-94
DOI 10.1007/BF00203397, PubMed 7496599

Andersen TI, Paus E, Nesland JM, McKenzie SJ, Børresen AL (1995)
Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour
Acta Oncol, 34 (4), 499-504
DOI 10.3109/02841869509094014, PubMed 7605658

Skullerud K, Stenwig AE, Brandtzaeg P, Nesland JM, Kerty E, Langmoen I, Saeter G (1995)
Intracranial primary leiomyosarcoma arising in a teratoma of the pineal area
Clin Neuropathol, 14 (4), 245-8
PubMed 8521631

Lopes JM, Bjerkehagen B, Holm R, Bruland O, Sobrinho-Simões M, Nesland JM (1995)
Proliferative activity of synovial sarcoma: an immunohistochemical evaluation of Ki-67 labeling indices of 52 primary and recurrent tumors
Ultrastruct Pathol, 19 (2), 101-6
DOI 10.3109/01913129509014609, PubMed 7792946

Suo Z, Su W, Holm R, Nesland JM (1995)
Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas
Anticancer Res, 15 (6B), 2797-8
PubMed 8669867

Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fosså SD (1995)
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma
Br J Urol, 75 (1), 26-32
DOI 10.1111/j.1464-410x.1995.tb07227.x, PubMed 7531589

Lothe RA, Slettan A, Saeter G, Brøgger A, Børresen AL, Nesland JM (1995)
Alterations at chromosome 17 loci in peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 54 (1), 65-73
DOI 10.1097/00005072-199501000-00008, PubMed 7815081

Nesland JM, Børresen AL, Andersson LC (1994)
[Molecular pathology. A new diagnostic dimension]
Tidsskr Nor Laegeforen, 114 (26), 3047-8
PubMed 7974419

Høie J, Jørgensen OG, Nesland JM, Møller P, Bjøro K (1994)
[Medullary thyroid carcinoma--familial or sporadic disease?]
Tidsskr Nor Laegeforen, 114 (25), 2951-4
PubMed 7974404

Giercksky KE, Qvist H, Giercksky TC, Warloe T, Nesland JM (1994)
Multiple glove powder granulomas masquerading as peritoneal carcinomatosis
J Am Coll Surg, 179 (3), 299-304
PubMed 8069426

Holm R, Nesland JM (1994)
[Microwave oven in immunohistochemistry. An important tool for determination of antigens in formalin-fixed and paraffin-embedded tissue]
Tidsskr Nor Laegeforen, 114 (20), 2392-4
PubMed 7527943

Rosenberg C, Andersen TI, Nesland JM, Lier ME, Brøgger A, Børresen AL (1994)
Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques
Cancer Genet Cytogenet, 75 (1), 1-5
DOI 10.1016/0165-4608(94)90207-0, PubMed 8039157

Makar AP, Holm R, Kristensen GB, Nesland JM, Tropé CG (1994)
The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
Int J Gynecol Cancer, 4 (3), 194-199
DOI 10.1046/j.1525-1438.1994.04030194.x, PubMed 11578406

Holm R, Tanum G, Karlsen F, Nesland JM (1994)
Prevalence and physical state of human papillomavirus DNA in anal carcinomas
Mod Pathol, 7 (4), 449-53
PubMed 8066073

Berner A, Harvei S, Tretli S, Fosså SD, Nesland JM (1994)
Prostatic carcinoma: a multivariate analysis of prognostic factors
Br J Cancer, 69 (5), 924-30
DOI 10.1038/bjc.1994.179, PubMed 7514029

Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O (1994)
In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma
Neurosurgery, 34 (4), 649-55; discussion 655-6
DOI 10.1227/00006123-199404000-00012, PubMed 8008162

Bjerklund Johansen TE, Majak M, Nesland JM (1994)
Testicular histology after treatment with the new antiandrogen Casodex for carcinoma of the prostate. A preliminary report
Scand J Urol Nephrol, 28 (1), 67-70
DOI 10.3109/00365599409180473, PubMed 8009196

Holm R, Nesland JM (1994)
Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland
J Pathol, 172 (3), 267-72
DOI 10.1002/path.1711720307, PubMed 8195930

Abeler VM, Holm R, Nesland JM, Kjørstad KE (1994)
Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients
Cancer, 73 (3), 672-7
DOI 10.1002/1097-0142(19940201)73:3<672::aid-cncr2820730328>3.0.co;2-r, PubMed 8299089

Lopes JM, Bjerkehagen B, Holm R, Bruland O, Sobrinho-Simões M, Nesland JM (1994)
Immunohistochemical profile of synovial sarcoma with emphasis on the epithelial-type differentiation. A study of 49 primary tumours, recurrences and metastases
Pathol Res Pract, 190 (2), 168-77
DOI 10.1016/S0344-0338(11)80708-9, PubMed 7520165

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277

David L, Nesland JM, Holm R, Sobrinho-Simões M (1994)
Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients
Cancer, 73 (3), 518-27
DOI 10.1002/1097-0142(19940201)73:3<518::aid-cncr2820730305>3.0.co;2-t, PubMed 8299074

Erlandson RA, Nesland JM (1994)
Tumors of the endocrine/neuroendocrine system: an overview
Ultrastruct Pathol, 18 (1-2), 149-70
DOI 10.3109/01913129409016286, PubMed 7910711

Bjerkehagen B, Fosså SD, Raabe N, Holm R, Nesland JM (1994)
Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbB-2 protein, neuron-specific enolase, Phe 5, chromogranin, laminin and collagen type IV
Eur Urol, 26 (4), 334-9
DOI 10.1159/000475410, PubMed 7713133

Reed W, Bryne M, Clausen H, Dabelsteen E, Nesland JM (1994)
Simple mucins (T, sialosyl-T, Tn and sialosyl-Tn) are not diagnostic for malignant breast lesions
Anticancer Res, 14 (2B), 609-15
PubMed 7516636

Berner A, Danielsen HE, Juul NO, Juul ME, Pettersen EO, Reith A, Nesland JM, Fosså SD (1993)
Caveats in the estimation of DNA-ploidy in paraffin embedded specimens of primary prostate cancer and lymph node metastases by flow and image cytometry
Anal Cell Pathol, 5 (6), 339-52
PubMed 8305330

Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL (1993)
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
DOI 10.1002/path.1711710207, PubMed 8283348

Peng Q, Brown SB, Moan J, Nesland JM, Wainwright M, Griffiths J, Dixon B, Cruse-Sawyer J, Vernon D (1993)
Biodistribution of a methylene blue derivative in tumor and normal tissues of rats
J Photochem Photobiol B, 20 (1), 63-71
DOI 10.1016/1011-1344(93)80132-s, PubMed 8229471

Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL (1993)
Prognostic significance of TP53 alterations in breast carcinoma
Br J Cancer, 68 (3), 540-8
DOI 10.1038/bjc.1993.383, PubMed 8102535

David L, Nesland JM, Funderud S, Sobrinho-Simões M (1993)
CDw75 antigen expression in human gastric carcinoma and adjacent mucosa
Cancer, 72 (5), 1522-7
DOI 10.1002/1097-0142(19930901)72:5<1522::aid-cncr2820720505>3.0.co;2-f, PubMed 8348485

Fosså SD, Berner AA, Jacobsen AB, Waehre H, Kvarstein B, Urnes T, Ogreid P, Johansen TE, Silde J, Nesland JM (1993)
Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer
Br J Cancer, 68 (3), 572-8
DOI 10.1038/bjc.1993.388, PubMed 8102536

Berner A, Danielsen HE, Pettersen EO, Fosså SD, Reith A, Nesland JM (1993)
DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas
Anal Quant Cytol Histol, 15 (4), 247-52
PubMed 7691062

Berner A, Nesland JM, Waehre H, Silde J, Fosså SD (1993)
Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens
Br J Cancer, 68 (2), 380-4
DOI 10.1038/bjc.1993.344, PubMed 7688548

Carneiro F, David L, Seruca R, Castedo S, Nesland JM, Sobrinho-Simões M (1993)
Hyperplastic polyposis and diffuse carcinoma of the stomach. A study of a family
Cancer, 72 (2), 323-9
DOI 10.1002/1097-0142(19930715)72:2<323::aid-cncr2820720204>3.0.co;2-g, PubMed 8319165

Suo Z, Holm R, Nesland JM (1993)
Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours
Histopathology, 23 (1), 45-54
DOI 10.1111/j.1365-2559.1993.tb01182.x, PubMed 7690007

Holm R, Abeler VM, Skomedal H, Nesland JM (1993)
Overexpression of p53 protein and c-erbB-2 protein in small cell carcinoma of the cervix uteri
Zentralbl Pathol, 139 (2), 153-6
PubMed 8103676

Reed W, Erikstein BK, Funderud S, Lilleng R, Tvedt K, Nesland JM (1993)
CDw75 antigen expression in breast lesions
Pathol Res Pract, 189 (4), 394-8
DOI 10.1016/S0344-0338(11)80325-0, PubMed 7688897

Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fosså SD, Tveit KM (1993)
Flow cytometric DNA analysis as prognostic factor in human breast carcinoma
Pathol Res Pract, 189 (4), 405-10
DOI 10.1016/S0344-0338(11)80327-4, PubMed 8351241

Pettersen EO, Larsen RO, Dornish JM, Børretzen B, Juul ME, Aastveit TE, Nesland JM, Rofstad EK, Oftebro R (1993)
Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H)
Br J Cancer, 67 (4), 650-6
DOI 10.1038/bjc.1993.121, PubMed 8471421

Berner A, Jacobsen AB, Fosså SD, Nesland JM (1993)
Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder
Histopathology, 22 (4), 327-33
DOI 10.1111/j.1365-2559.1993.tb00131.x, PubMed 8099896

Makar AP, Kristensen GB, Nesland J, Børmer OP, Tropé CG (1993)
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies
Int J Gynecol Cancer, 3 (2), 116-121
DOI 10.1046/j.1525-1438.1993.03020116.x, PubMed 11578331

Helseth A, Bautch VL, Haug E, Holm R, Nesland JM, Fodstad O (1993)
[Transgenic mice as animal model of Cushing's syndrome]
Tidsskr Nor Laegeforen, 113 (2), 206-10
PubMed 8381565

Gorczyca W, Holm R, Nesland JM (1993)
Laminin production and fibronectin immunoreactivity in breast carcinomas
Anticancer Res, 13 (4), 851-8
PubMed 8394677

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL (1993)
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712

Horvath G, Baldetorp B, Fernö M, Johansson M, Nesland J, Tropé C (1993)
Effect of estradiol on tumor growth, cell kinetics and p53 oncoprotein expression in human endometrial adenocarcinoma heterotransplanted into nude mice
In Vivo, 7 (5), 451-6
PubMed 8110990

Holm R, Helseth A, Nesland JM, Bautch VL (1993)
ACTH-producing pituitary tumors in transgenic mice. An ultrastructural and immunoelectron microscopic study
J Submicrosc Cytol Pathol, 25 (1), 29-36
PubMed 8384929

Suo Z, Qvist H, Su W, Holm R, Giercksky KE, Nesland JM (1993)
Undifferentiated carcinoma: an immunohistochemical and ultrastructural study
Anticancer Res, 13 (3), 643-9
PubMed 8317892

Holm R, Skomedal H, Helland A, Kristensen G, Børresen AL, Nesland JM (1993)
Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri
J Pathol, 169 (1), 21-6
DOI 10.1002/path.1711690105, PubMed 8433212

Lopes JM, Bjerkehagen B, Sobrinho-Simoes M, Nesland JM (1993)
The ultrastructural spectrum of synovial sarcomas: a study of the epithelial type differentiation of primary tumors, recurrences, and metastases
Ultrastruct Pathol, 17 (2), 137-51
DOI 10.3109/01913129309084034, PubMed 8391175

Vergote I, Larsen RH, de Vos L, Nesland JM, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K (1992)
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model
Gynecol Oncol, 47 (3), 366-72
DOI 10.1016/0090-8258(92)90141-5, PubMed 1473751

Peng Q, Moan J, Warloe T, Nesland JM, Rimington C (1992)
Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma
Int J Cancer, 52 (3), 433-43
DOI 10.1002/ijc.2910520318, PubMed 1399120

Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B, Børresen AL (1992)
Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors
J Natl Cancer Inst, 84 (14), 1100-8
DOI 10.1093/jnci/84.14.1100, PubMed 1619684

Sund BS, Topstad TK, Nesland JM (1992)
A case of juvenile papillomatosis of the male breast
Cancer, 70 (1), 126-8
DOI 10.1002/1097-0142(19920701)70:1<126::aid-cncr2820700121>3.0.co;2-9, PubMed 1606534

Kaern J, Iversen T, Tropé C, Pettersen EO, Nesland JM (1992)
Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method
Int J Gynecol Cancer, 2 (4), 169-174
DOI 10.1046/j.1525-1438.1992.02040169.x, PubMed 11576255

David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Børresen AL, Sobrinho-Simões M (1992)
c-erbB-2 expression in primary gastric carcinomas and their metastases
Mod Pathol, 5 (4), 384-90
PubMed 1353880

Vergote I, De Vos L, Fjeld J, Nesland J, Kierulf B, Michaelsen T, Nustad K (1992)
B-cell hybridoma as intraperitoneal tumor model: correlation between tumor growth and monoclonal antibody production
Hybridoma, 11 (3), 323-31
DOI 10.1089/hyb.1992.11.323, PubMed 1500068

Holm R, Karlsen F, Nesland JM (1992)
In situ hybridization with nonisotopic probes using different detection systems
Mod Pathol, 5 (3), 315-9
PubMed 1323105

Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Børresen AL (1992)
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Genes Chromosomes Cancer, 4 (2), 113-21
DOI 10.1002/gcc.2870040203, PubMed 1373310

Reed W, Gundersen S, Lønning PE, Nesland JM (1992)
[Prognostic parameters in localized breast cancer]
Tidsskr Nor Laegeforen, 112 (6), 757-9
PubMed 1561596

Lilleng R, Hagmar BM, Nesland JM (1992)
C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast
Mod Pathol, 5 (1), 41-7
PubMed 1347423

Logothetou-Rella H, Karayiannis A, Vamvassakis E, Livaditou A, Pikramenos D, Nesland JM, Dimopoulos C (1992)
A cytologic, ultrastructural and immunocytochemical comparison of tumor cells and cell cultures originating in invasive bladder carcinoma
Eur Urol, 21 (2), 146-50
DOI 10.1159/000474822, PubMed 1379923

Suo Z, Holm R, Nesland JM (1992)
Squamous cell carcinomas, an immunohistochemical and ultrastructural study
Anticancer Res, 12 (6B), 2025-31
PubMed 1284199

David L, Nesland JM, Clausen H, Carneiro F, Sobrinho-Simões M (1992)
Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases
APMIS Suppl, 27, 162-72
PubMed 1520525

Fosså SD, Nesland JM, Pettersen EO, Amellem O, Waehre H, Heimdal K (1991)
DNA ploidy in primary testicular cancer
Br J Cancer, 64 (5), 948-52
DOI 10.1038/bjc.1991.432, PubMed 1931622

Børresen AL, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH (1991)
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
Proc Natl Acad Sci U S A, 88 (19), 8405-9
DOI 10.1073/pnas.88.19.8405, PubMed 1924299

Nesland JM (1991)
[p53--a gene to mark itself]
Tidsskr Nor Laegeforen, 111 (22), 2721-2
PubMed 1948860

Peng Q, Farrants GW, Madslien K, Bommer JC, Moan J, Danielsen HE, Nesland JM (1991)
Subcellular localization, redistribution and photobleaching of sulfonated aluminum phthalocyanines in a human melanoma cell line
Int J Cancer, 49 (2), 290-5
DOI 10.1002/ijc.2910490225, PubMed 1879972

Abeler VM, Kjørstad KE, Nesland JM (1991)
Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases
Cancer, 68 (1), 98-105
DOI 10.1002/1097-0142(19910701)68:1<98::aid-cncr2820680120>3.0.co;2-r, PubMed 2049761

Berner A, Nesland JM (1991)
Endocrine profile in gastric carcinomas. An immunohistochemical study
Histol Histopathol, 6 (3), 317-23
PubMed 1725759

Sambade C, Franssila K, Cameselle-Teijeiro J, Nesland J, Sobrinho-Simões M (1991)
Hyalinizing trabecular adenoma: A misnomer for a peculiar tumor of the thyroid gland
Endocr Pathol, 2 (2), 83-91
DOI 10.1007/BF02915330, PubMed 32138392

Fosså SD, Nesland JM, Waehre H, Amellem O, Pettersen EO (1991)
DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I
Cancer, 67 (7), 1874-7
DOI 10.1002/1097-0142(19910401)67:7<1874::aid-cncr2820670710>3.0.co;2-6, PubMed 1848470

Nesland JM (1991)
[The mitochondrium--a fascinating organelle]
Tidsskr Nor Laegeforen, 111 (2), 176
PubMed 1705367

Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Børresen AL (1991)
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329

Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K (1991)
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562

Jebsen PW, Hagmar BM, Nesland JM (1991)
Metaplastic breast carcinoma. A diagnostic problem in fine needle aspiration biopsy
Acta Cytol, 35 (4), 396-402
PubMed 1718111

Rofstad EK, Wahl A, Hystad ME, Nesland JM, Stokke T (1991)
Establishment in monolayer culture and characterization of four human melanoma cell lines
Virchows Arch B Cell Pathol Incl Mol Pathol, 60 (3), 189-97
DOI 10.1007/BF02899546, PubMed 1679270

Peng Q, Moan J, Nesland JM, Rimington C (1990)
Aluminum phthalocyanines with asymmetrical lower sulfonation and with symmetrical higher sulfonation: a comparison of localizing and photosensitizing mechanism in human tumor LOX xenografts
Int J Cancer, 46 (4), 719-26
DOI 10.1002/ijc.2910460428, PubMed 2210887

Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T, Tveit KM, Nesland JM (1990)
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
Br J Cancer, 62 (4), 585-90
DOI 10.1038/bjc.1990.334, PubMed 1977466

Rofstad EK, Wahl A, Stokke T, Nesland JM (1990)
Establishment and characterization of six human melanoma xenograft lines
APMIS, 98 (10), 945-53
DOI 10.1111/j.1699-0463.1990.tb05019.x, PubMed 2245014

Peng Q, Nesland JM, Moan J, Evensen JF, Kongshaug M, Rimington C (1990)
Localization of fluorescent Photofrin II and aluminum phthalocyanine tetrasulfonate in transplanted human malignant tumor LOX and normal tissues of nude mice using highly light-sensitive video intensification microscopy
Int J Cancer, 45 (5), 972-9
DOI 10.1002/ijc.2910450533, PubMed 2139867

Sobrinho-Simoes M, Sambade C, Nesland JM, Holm R, Damjanov I (1990)
Lectin histochemistry and ultrastructure of medullary carcinoma of the thyroid gland
Arch Pathol Lab Med, 114 (4), 369-75
PubMed 1690976

Berner A, Børmer O, Marton PF, Nesland JM (1990)
Distribution of the carcinoembryonic antigen CEA in gastric lesions. Immunohistochemical testing of three novel monoclonal antibodies
Histol Histopathol, 5 (2), 199-204
PubMed 2134373

Jacobsen AB, Nesland JM, Fosså SD, Pettersen EO (1990)
Human chorionic gonadotropin, neuron specific enolase and deoxyribonucleic acid flow cytometry in patients with high grade bladder carcinoma
J Urol, 143 (4), 706-9
DOI 10.1016/s0022-5347(17)40066-8, PubMed 2313795

Logothetou-Rella H, Nesland JM, Kipiotis D, Paraschou E, Sechas M, Varonos DD (1990)
Canine capillary formation in vitro
Histol Histopathol, 5 (1), 55-64
PubMed 2134356

Fosså SD, Nesland JM, Melvik JE, Jacobsen AB, Moe B (1990)
Prediction of objective response to recombinant interferon-alpha with or without vinblastine in metastatic renal cell carcinoma
Acta Oncol, 29 (3), 303-6
DOI 10.3109/02841869009090002, PubMed 2363942

Dasović-Knezević M, Børmer O, Holm R, Høie J, Sobrinho-Simões M, Nesland JM (1989)
Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies
Mod Pathol, 2 (6), 610-7
PubMed 2587568

Ottestad L, Tveit KM, Hannisdal E, Skrede M, Nesland JM, Gundersen S, Pihl A (1989)
Colony forming ability of human breast carcinomas: lack of prognostic significance
Br J Cancer, 60 (2), 216-9
DOI 10.1038/bjc.1989.254, PubMed 2765368

Logothetou-Rella H, Kotoulas IG, Nesland JM, Kipiotis D, Abazis D (1989)
Early human trophoblast cell cultures. A morphological and immunocytochemical study
Histol Histopathol, 4 (3), 367-74
PubMed 2520471

Kotańska KM, Holm R, Ottestad L, Nesland JM (1989)
An ultrastructural study of benign and malignant breast epithelial cells. A search for tonofilaments
J Submicrosc Cytol Pathol, 21 (3), 469-74
PubMed 2551480

Holm R, Nesland JM, Attramadal A, Halse J, Johannessen JV (1989)
Null cell adenomas of the pituitary gland. An immunohistochemical study
J Pathol, 158 (3), 213-7
DOI 10.1002/path.1711580307, PubMed 2769482

Holm R, Nesland JM, Attramadal A, Reinli S, Johannessen JV (1989)
Mixed growth hormone- and prolactin cell adenomas of the pituitary gland. An immunoelectron microscopic study
J Submicrosc Cytol Pathol, 21 (2), 339-50
PubMed 2752363

Saeter G, Schwarze PE, Nesland JM, Seglen PO (1989)
Diploid nature of hepatocellular tumours developing from transplanted preneoplastic liver cells
Br J Cancer, 59 (2), 198-205
DOI 10.1038/bjc.1989.41, PubMed 2930686

Holm R, Farrants GW, Nesland JM, Sobrinho-Simões M, Jørgensen OG, Johannessen JV (1989)
Ultrastructural and electron immunohistochemical features of medullary thyroid carcinoma
Virchows Arch A Pathol Anat Histopathol, 414 (5), 375-84
DOI 10.1007/BF00718620, PubMed 2499093

Sambade C, Sarabando F, Nesland JM, Sobrinho Simões M (1989)
Hyalinizing trabecular adenoma of the thyroid (case of the Ullensvang course). Hyalinizing spindle cell tumor of the thyroid with dual differentiation (variant of the so-called hyalinizing trabecular adenoma)
Ultrastruct Pathol, 13 (2-3), 275-80
DOI 10.3109/01913128909057445, PubMed 2734856

Johansen TE, Clausen OP, Nesland JM (1989)
The effect of non-union of testis and epididymis and of cryptorchidism on the development of epididymis and ductus deferens in the rat
Andrologia, 21 (5), 441-8
PubMed 2573293

Seglen PO, Skomedal H, Saeter G, Schwarze PE, Nesland JM (1989)
Neuroendocrine dysdifferentiation and bombesin production in carcinogen-induced hepatocellular rat tumours
Carcinogenesis, 10 (1), 21-5
DOI 10.1093/carcin/10.1.21, PubMed 2910524

Falkmer S, Askensten U, Nesland JM (1989)
Tumour pathology of the neuron-paraneuron system and its evolutionary background, with special attention to neuro-endocrine differentiation in prostate and mammary carcinomas
Arch Histol Cytol, 52 Suppl, 225-32
DOI 10.1679/aohc.52.suppl_225, PubMed 2510784

Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A (1988)
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells
Cancer Res, 48 (15), 4382-8
PubMed 3390834

Ottestad L, Tveit KM, Høifødt HK, Nesland JM, Vaage S, Høie J, Lund E, Pihl A (1988)
Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens
Br J Cancer, 58 (1), 8-12
DOI 10.1038/bjc.1988.151, PubMed 3048354

Ottestad LO, Tveit KM, Nesland JM, Dybsjord I, Børmer O, Høie J, Pihl A (1988)
An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay
Histol Histopathol, 3 (3), 269-74
PubMed 2980233

Saeter G, Schwarze PE, Nesland JM, Juul N, Pettersen EO, Seglen PO (1988)
The polyploidizing growth pattern of normal rat liver is replaced by divisional, diploid growth in hepatocellular nodules and carcinomas
Carcinogenesis, 9 (6), 939-45
DOI 10.1093/carcin/9.6.939, PubMed 3370757

Nesland JM, Holm R, Johannessen JV, Gould VE (1988)
Neuroendocrine differentiation in breast lesions
Pathol Res Pract, 183 (2), 214-21
DOI 10.1016/S0344-0338(88)80048-7, PubMed 3290869

Saeter G, Schwarze PE, Nesland JM, Seglen PO (1988)
2-Acetylaminofluorene promotion of liver carcinogenesis by a non-cytotoxic mechanism
Carcinogenesis, 9 (4), 581-7
DOI 10.1093/carcin/9.4.581, PubMed 2895691

Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A (1988)
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX
Int J Cancer, 41 (3), 442-9
DOI 10.1002/ijc.2910410322, PubMed 3346110

Sobrinho-Simões M, Nesland JM, Johannessen JV (1988)
Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid
Am J Clin Pathol, 89 (2), 264-7
DOI 10.1093/ajcp/89.2.264, PubMed 3341287

Logothetou-Rella H, Nesland JM, Vamvassakis E, Karayiannis A, Hadjiminas J, Dimopoulos C (1988)
Common characteristics of primary cell cultures originated from invasive urothelial carcinoma
Eur Urol, 14 (1), 61-4
DOI 10.1159/000472899, PubMed 3342808

Johansen TE, Clausen OP, Nesland JM (1988)
A comparative study of the effects of non-union of testis and epididymis and cryptorchidism on testicular development and spermatogenesis in the rat
Andrologia, 20 (3), 189-201
DOI 10.1111/j.1439-0272.1988.tb01055.x, PubMed 2902815

Logothetou-Rella H, Nesland JM, Karayiannis A, Dimopoulos C (1988)
Growth characteristics of cultured human normal bladder epithelial cells: a comparison with urothelial carcinoma cell cultures
Eur Urol, 15 (3-4), 259-63
DOI 10.1159/000473448, PubMed 3215260

Logothetou-Rella H, Vamvassakis E, Nesland JM, Hadjiminas J, Dimopoulos C (1988)
Morphological and immunohistochemical characteristics of a cell line originated from noninvasive human bladder transitional-cell carcinoma
Eur Urol, 14 (1), 65-71
DOI 10.1159/000472900, PubMed 3342809

Nesland JM, Holm R, Ottestad L, Karlsen KO, Johannessen JV (1988)
Neuroendocrine activity in metastatic breast carcinomas
APMIS Suppl, 2, 204-14
PubMed 2846016

Erikstein B, Nesland JM, Ottestad L, Lund E, Johannessen JV (1988)
Neuron specific enolase-positive breast carcinomas
Histol Histopathol, 3 (1), 97-102
PubMed 2980214

Holm R, Nesland JM, Attramadal A, Johannessen JV (1988)
Double-staining methods at the ultrastructural level applying colloidal gold conjugates
Ultrastruct Pathol, 12 (3), 279-90
DOI 10.3109/01913128809098040, PubMed 2456636

Abeler V, Kjørstad KE, Nesland JM (1988)
Small cell carcinoma of the ovary. A report of six cases
Int J Gynecol Pathol, 7 (4), 315-29
DOI 10.1097/00004347-198812000-00003, PubMed 2852647

Lunde S, Nesland JM, Holm R, Johannessen JV (1987)
Breast carcinomas with protein S-100 immunoreactivity. An immunocytochemical and ultrastructural study
Pathol Res Pract, 182 (5), 627-31
PubMed 2825146

Holm R, Sobrinho-Simões M, Nesland JM, Sambade C, Johannessen JV (1987)
Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity?
Lab Invest, 57 (3), 258-68
PubMed 3626517

Nesland JM, Holm R, Lunde S, Johannessen JV (1987)
Diagnostic problems in breast pathology: the benefit of ultrastructural and immunocytochemical analysis
Ultrastruct Pathol, 11 (2-3), 293-311
DOI 10.3109/01913128709048328, PubMed 3035768

Nesland JM, Lunde S, Holm R, Johannessen JV (1987)
Electron microscopy and immunostaining of the normal breast and its benign lesions. A search for neuroendocrine cells
Histol Histopathol, 2 (1), 73-7
PubMed 2980706

Lunde S, Nesland JM, Holm R, Johannessen JV (1987)
A urinary bladder tumor in a 65-year-old man
Ultrastruct Pathol, 11 (1), 79-82
DOI 10.3109/01913128709023186, PubMed 3824568

Bjerkås I, Nesland JM (1987)
Brain and spinal cord lesions in encephalitozoonosis in the blue fox
Acta Vet Scand, 28 (1), 15-22
DOI 10.1186/BF03548252, PubMed 3120524

Saeter G, Schwarze PE, Nesland JM, Seglen PO (1987)
Transplantation of preneoplastic rat hepatocytes by intraportal injection
Toxicol Pathol, 15 (1), 78-81
DOI 10.1177/019262338701500110, PubMed 3554470

Kjellevold K, Nesland JM, Holm R, Johannessen JV (1986)
Multicystic peritoneal mesothelioma
Pathol Res Pract, 181 (6), 767-73
DOI 10.1016/S0344-0338(86)80056-5, PubMed 2436202

Nesland JM, Pettersen EO, Fosså SD, Høie J, Johannessen JV (1986)
Nuclear DNA content in breast carcinomas with neuroendocrine differentiation
J Pathol, 150 (3), 181-5
DOI 10.1002/path.1711500306, PubMed 3027292

Nesland JM, Holm R, Johannessen JV (1986)
A study of different markers for neuroendocrine differentiation in breast carcinomas
Pathol Res Pract, 181 (5), 524-30
DOI 10.1016/S0344-0338(86)80144-3, PubMed 2431399

Sobrinho-Simões M, Stenwig AE, Nesland JM, Holm R, Johannessen JV (1986)
A mucinous carcinoma of the thyroid
Pathol Res Pract, 181 (4), 464-71
DOI 10.1016/S0344-0338(86)80086-3, PubMed 3020530

Fodstad O, Brøgger A, Bruland O, Solheim OP, Nesland JM, Pihl A (1986)
Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma
Int J Cancer, 38 (1), 33-40
DOI 10.1002/ijc.2910380107, PubMed 3459716

Eker R, Nesland JM, Andersen A, Johannessen JV (1986)
Prognostic factors in renal cell carcinoma
Histol Histopathol, 1 (3), 255-70
PubMed 2980119

Holm R, Sobrinho-Simões M, Nesland JM, Johannessen JV (1986)
Concurrent production of calcitonin and thyroglobulin by the same neoplastic cells
Ultrastruct Pathol, 10 (3), 241-8
DOI 10.3109/01913128609032223, PubMed 3715999

Lunde S, Nesland JM, Holm R, Johannessen JV (1986)
Primary malignant fibrous histiocytoma of the breast
Histol Histopathol, 1 (1), 27-32
PubMed 2856533

Nesland JM, Holm R, Johannessen JV (1986)
Spindle cell tumor in the breast
Ultrastruct Pathol, 10 (5), 415-9
DOI 10.3109/01913128609007195, PubMed 2429416

Pettersen EO, Schwarze PE, Dornish JM, Nesland JM (1986)
Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma
Anticancer Res, 6 (2), 147-52
PubMed 3707050

Rode L, Nesland JM, Johannessen JV (1986)
A spindle cell breast lesion in a 54-year-old woman
Ultrastruct Pathol, 10 (5), 421-5
DOI 10.3109/01913128609007196, PubMed 2429417

Nesland JM, Holm R, Johannessen JV, Gould VE (1986)
Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations
J Pathol, 148 (1), 35-43
DOI 10.1002/path.1711480107, PubMed 3003312

Aamdal S, Fodstad O, Nesland JM, Pihl A (1985)
Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice
Br J Cancer, 51 (3), 347-56
DOI 10.1038/bjc.1985.46, PubMed 3970811

Nesland JM, Holm R, Johannessen JV (1985)
Ultrastructural and immunohistochemical features of lobular carcinoma of the breast
J Pathol, 145 (1), 39-52
DOI 10.1002/path.1711450104, PubMed 2578561

Sobrinho-Simões MA, Nesland JM, Holm R, Johannessen JV (1985)
Transmission electron microscopy and immunocytochemistry in the diagnosis of thyroid tumors
Ultrastruct Pathol, 9 (3-4), 255-75
DOI 10.3109/01913128509074581, PubMed 3911530

Nesland JM, Sobrinho-Simões MA, Holm R, Johannessen JV (1985)
Primitive neuroectodermal tumor (peripheral neuroblastoma)
Ultrastruct Pathol, 9 (1-2), 59-64
DOI 10.3109/01913128509055486, PubMed 3003993

Sobrinho-Simões MA, Nesland JM, Johannessen JV (1985)
A mucin-producing tumor in the thyroid gland
Ultrastruct Pathol, 9 (3-4), 277-81
DOI 10.3109/01913128509074582, PubMed 4090007

Sobrinho-Simões M, Nesland JM, Johannessen JV (1985)
Farewell to the dual histogenesis of thyroid tumors?
Ultrastruct Pathol, 8 (2-3), iii-v
DOI 10.3109/01913128509142145, PubMed 2865835

Nesland JM, Johannessen JV (1985)
Spindle cell tumor of the ovary
Ultrastruct Pathol, 8 (4), 363-8
DOI 10.3109/01913128509141525, PubMed 3001986

Nesland JM, Sobrinho-Simões MA, Holm R, Sambade MC, Johannessen JV (1985)
Hürthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry
Ultrastruct Pathol, 8 (4), 269-90
DOI 10.3109/01913128509141518, PubMed 4082297

Sobrinho-Simões MA, Nesland JM, Holm R, Sambade MC, Johannessen JV (1985)
Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study
Ultrastruct Pathol, 8 (2-3), 131-42
DOI 10.3109/01913128509142147, PubMed 4060255

Holm R, Sobrinho-Simões M, Nesland JM, Gould VE, Johannessen JV (1985)
Medullary carcinoma of the thyroid gland: an immunocytochemical study
Ultrastruct Pathol, 8 (1), 25-41
DOI 10.3109/01913128509141506, PubMed 3901454

Nesland JM, Sobrinho-Simões MA, Holm R, Johannessen JV (1985)
Organoid tumor in the thyroid gland
Ultrastruct Pathol, 9 (1-2), 65-70
DOI 10.3109/01913128509055487, PubMed 4089997

Nesland JM, Memoli VA, Holm R, Gould VE, Johannessen JV (1985)
Breast carcinomas with neuroendocrine differentiation
Ultrastruct Pathol, 8 (2-3), 225-40
DOI 10.3109/01913128509142155, PubMed 4060259

Wibe E, Berg JP, Tveit KM, Nesland JM, Lunde S (1984)
Multicellular spheroids grown directly from human tumour material
Int J Cancer, 34 (1), 21-6
DOI 10.1002/ijc.2910340105, PubMed 6746116

Nesland JM, Langholm R, Marton PF (1984)
Hexagonal crystals in the bone marrow in patients with myeloproliferative disease and preleukaemia
Scand J Haematol, 32 (5), 552-8
DOI 10.1111/j.1600-0609.1984.tb02199.x, PubMed 6328640

Nesland JM, Johannessen JV (1984)
Scanning electron microscopy of the human breast and its disorders
J Submicrosc Cytol, 16 (2), 349-57
PubMed 6325723

Nesland JM, Johannessen JV (1984)
Small cell tumor in a 24-year-old male
Ultrastruct Pathol, 6 (4), 341-6
DOI 10.3109/01913128409018592, PubMed 6485124

Nesland JM, Høie J, Johannessen JV (1983)
The fine structure of the human breast and its benign disorders
Diagn Histopathol, 6 (2), 51-67
PubMed 6319095

Nesland JM, Olafsson J, Sobrinho-Simöes M (1981)
Plasmacytoid myoepithelioma of the palate
J Oral Pathol, 10 (1), 14-21
DOI 10.1111/j.1600-0714.1981.tb01243.x, PubMed 6259307

Sobrinho-Simões M, Nesland JM, Johannessen JV (1981)
Diagnostic ultrastructural pathology--sub-speciality or special stain?
Diagn Histopathol, 4 (3), 223-36
PubMed 7273994

Solheim LF, Hagen R, Nesland JM (1980)
[Synovial chondromatosis of the ankle joint]
Tidsskr Nor Laegeforen, 100 (28), 1666-7
PubMed 7444912

Solheim LF, Wennberg JE, Nesland JM (1980)
Granular cell myoblastoma of the hands. Report of a child with multiple tumors
Arch Orthop Trauma Surg (1978), 97 (3), 231-2
DOI 10.1007/BF00389732, PubMed 6255894

Review articles

Berner A, Lund-Iversen M, Nesland JM (2011)
Fine needle aspirations in oncology
Arkh Patol, 73 (4), 21-6
PubMed 22164426

Knopp S, Tropè C, Nesland JM, Holm R (2009)
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
J Clin Pathol, 62 (3), 212-8
DOI 10.1136/jcp.2008.057240, PubMed 19251952

Knopp S, Nesland JM, Tropé C (2008)
SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
Surg Oncol, 17 (3), 219-25
DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Davidson B, Reich R, Risberg B, Nesland JM (2002)
The biological role and regulation of matrix metalloproteinases (MMP) in cancer
Arkh Patol, 64 (3), 47-53
PubMed 15338725

Suo Z, Nesland JM (2002)
Type 1 protein tyrosine kinases in breast carcinoma: a review
Ultrastruct Pathol, 26 (3), 125-35
DOI 10.1080/01913120290076784, PubMed 12184370

Giercksky HE, Nesland JM (2000)
[Microdissection--an important tool in molecular biology]
Tidsskr Nor Laegeforen, 120 (5), 598-600
PubMed 10833921

Kvalheim G, Naume B, Nesland JM (1999)
Minimal residual disease in breast cancer
Cancer Metastasis Rev, 18 (1), 101-8
DOI 10.1023/a:1006216504892, PubMed 10505549

Moan J, Peng Q, Sorensen R, Iani V, Nesland JM (1998)
The biophysical foundations of photodynamic therapy
Endoscopy, 30 (4), 387-91
DOI 10.1055/s-2007-1001288, PubMed 9689514

Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997)
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges
Cancer, 79 (12), 2282-308
DOI 10.1002/(sici)1097-0142(19970615)79:12<2282::aid-cncr2>3.0.co;2-o, PubMed 9191516

Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM (1997)
5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research
Photochem Photobiol, 65 (2), 235-51
DOI 10.1111/j.1751-1097.1997.tb08549.x, PubMed 9066303

Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, Solheim OP, Sobrinho-Simões M, Nesland JM (1997)
Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance
Pathol Res Pract, 193 (1), 21-36
DOI 10.1016/s0344-0338(97)80090-8, PubMed 9112270

Peng Q, Moan J, Nesland JM (1996)
Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy
Ultrastruct Pathol, 20 (2), 109-129
DOI 10.3109/01913129609016306, PubMed 8882357

Nesland JM, Grude TH, Ottestad L, Johannessen JV (1992)
Invasive lobular carcinoma of the breast. The importance of an alveolar growth pattern
Pathol Annu, 27 Pt 1, 233-47
PubMed 1736244

Nesland JM, Sobrinho-Simoes M, Johannessen JV (1987)
Scanning electron microscopy of the human thyroid gland and its disorders
Scanning Microsc, 1 (4), 1797-810
PubMed 3433063

Nesland JM, Johannessen JV (1982)
Malignant breast lesions
J Submicrosc Cytol, 14 (3), 553-75
PubMed 6294315

Nesland JM, Millonig G, Wilson A, Johannessen JV (1982)
Rapid techniques in diagnostic electron microscopy
Ultrastruct Pathol, 3 (3), 295-300
DOI 10.3109/01913128209016655, PubMed 6183809

Other articles

Ji Z, Yang G, Shahzidi S, Tkacz-Stachowska K, Suo Z, Nesland JM, Peng Q (2020)
Corrigendum to "Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy" [Canc. Lett 244 (2006) 182-189]
Cancer Lett, 498, 244
DOI 10.1016/j.canlet.2020.10.026, PubMed 33109413

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003

Sudbo J, Ristimaki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M (2007)
Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions (Retraction of vol 39, pg 497, 2003)
Oral Oncol., 43 (4), 420
DOI 10.1016/j.oraloncology.2007.01.003

Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM (2006)
Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
Histopathology, 49 (3), 311-2
DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980

Nesland JM (2004)
Chronic cholecystitis
Ultrastruct Pathol, 28 (3), 121
DOI 10.1080/01913120490489441, PubMed 15471424

Nesland JM (2004)
Ultrastructural and molecular analysis of cribriform-morular variant of papillary thyroid carcinoma
Ultrastruct Pathol, 28 (2), 53
DOI 10.1080/01913120490434847, PubMed 15205104

Nesland JM (2004)
Ultrastructural examination and technical developments
Ultrastruct Pathol, 28 (1), 1
DOI 10.1080/01913120490275268, PubMed 14967592

Davidson B, Suo Z, Nesland JM (2004)
Malignant mesothelioma
Ultrastruct Pathol, 28 (4), 179-80
DOI 10.1080/01913120490518051, PubMed 15693629

Sudbø J, Ristimäki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M (2003)
Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions
Oral Oncol, 39 (5), 497-505 (Retracted)
DOI 10.1016/s1368-8375(03)00012-5, PubMed 12747975

Ikonomou IM, Nesland JM, Schjølseth SA, Heim S, Delabie J (2002)
Mantle cell lymphoma with Homer-Wright rosettes
Virchows Arch, 442 (2), 179-82
DOI 10.1007/s00428-002-0739-1, PubMed 12596071

Suo Z, Nesland JM (2002)
Barrett's esophagus: intestinal metaplasia or phenotypic shift of undifferentiated elements in the stem cells
Ultrastruct Pathol, 26 (2), 53-4
DOI 10.1080/01913120252959218, PubMed 12036092

Bukholm IR, Bukholm G, Nesland JM (2001)
Coexpression of cyclin A and beta-catenin and survival in breast cancer patients
Int J Cancer, 94 (1), 148-9
DOI 10.1002/ijc.1432, PubMed 11668490

Nesland JM (2000)
[Pathologic diagnosis--now and in the future]
Tidsskr Nor Laegeforen, 120 (2), 180
PubMed 10851909

Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjørseth A, Nesland JM (1996)
Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin
J Photochem Photobiol B, 34 (1), 95-6
DOI 10.1016/1011-1344(95)07268-3, PubMed 8765664

Karlsen F, Steen HB, Nesland JM (1995)
SYBR green I DNA staining increases the detection sensitivity of viruses by polymerase chain reaction
J Virol Methods, 55 (1), 153-6
DOI 10.1016/0166-0934(95)00053-w, PubMed 8576305

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179

Taccagni G, Sambade C, Nesland J, Terreni MR, Sobrinho-Simões M (1993)
Solitary fibrous tumour of the thyroid: clinicopathological, immunohistochemical and ultrastructural study of three cases
Virchows Arch A Pathol Anat Histopathol, 422 (6), 491-7
DOI 10.1007/BF01606459, PubMed 8333152

Børresen AL, Helland A, Nesland J, Holm R, Trope C, Kaern J (1992)
Papillomaviruses, p53, and cervical cancer
Lancet, 339 (8805), 1350-1
PubMed 1350005

Seruca R, David L, Holm R, Nesland JM, Fangan BM, Castedo S, Sobrinho-Simões M, Børresen AL (1992)
P53 mutations in gastric carcinomas
Br J Cancer, 65 (5), 708-10
DOI 10.1038/bjc.1992.149, PubMed 1586599

Kjønniksen I, Nesland JM, Pihl A, Fodstad O (1990)
Nude rat model for studying metastasis of human tumor cells to bone and bone marrow
J Natl Cancer Inst, 82 (5), 408-12
DOI 10.1093/jnci/82.5.408, PubMed 2304088

Nesland JM (1990)
The c-erB-2 protein
Ultrastruct Pathol, 14 (5), iii-iv
DOI 10.3109/01913129009007217, PubMed 1978949

Abeler V, Nesland JM (1989)
Alveolar soft-part sarcoma in the uterine cervix
Arch Pathol Lab Med, 113 (10), 1179-83
PubMed 2802951

Nesland JM, Johannessen JV (1989)
In situ hybridization
Ultrastruct Pathol, 13 (1), iii
DOI 10.3109/01913128909051154, PubMed 2465641

Sobrinho-Simões M, Sambade C, Nesland JM, Johannessen JV (1989)
Tall cell papillary carcinoma
Am J Surg Pathol, 13 (1), 79-80
DOI 10.1097/00000478-198901000-00014, PubMed 2909201

Sobrinho-Simões M, Nesland JM, Johannessen JV (1988)
What's going on in nerve sheath tumors?
Ultrastruct Pathol, 12 (1), iii-iv
DOI 10.3109/01913128809048471, PubMed 3354069

Sobrinho-Simões M, Nesland JM, Johannessen JV (1987)
Thyroid antibodies
Am J Surg Pathol, 11 (10), 821-4
DOI 10.1097/00000478-198710000-00011, PubMed 3661825

Nesland JM, Holm R, Sund BS, Johannessen JV (1986)
A thyroid tumor in a 57-year-old man
Ultrastruct Pathol, 10 (2), 197-202
DOI 10.3109/01913128609014595, PubMed 3515708

Glad WR, Nesland JM (1986)
Focal epithelial hyperplasia of the oral mucosa in two chimpanzees (Pan troglodytes)
Am J Primatol, 10 (1), 83-89
DOI 10.1002/ajp.1350100108, PubMed 31979497

Sobrinho-Simões M, Nesland JM, Johannessen JV (1985)
The mystery of the anemone cell tumor
Ultrastruct Pathol, 8 (4), iii-iv
DOI 10.3109/01913128509141517, PubMed 4082296

Kjellevold KH, Finseth I, Nesland JM (1984)
Collar button nuclei
Ultrastruct Pathol, 6 (2-3), 255-8
DOI 10.3109/01913128409018581, PubMed 6087529

Aguiar A, Sobrinto-Simões MM, Finseth I, Johannessen JV, Nesland JM (1984)
Uncombable hair
Arch Dis Child, 59 (1), 92-3
DOI 10.1136/adc.59.1.92-a, PubMed 6696511

Nesland JM, Kjellevold K, Finseth I, Fodstad O (1984)
Spherical bodies
Ultrastruct Pathol, 7 (1), 73-8
DOI 10.3109/01913128409141857, PubMed 6097001

Books

Nesland JM (1989)
Neuroendocrine expression in benign and malignant breast lesions
Department of Pathology, The Norwegian Radium Hospital andInstitute for Cancer Research, Oslo, 1 b. (flere pag.)
BIBSYS 890112827, ISBN 82-90187-49-1

Book chapters

Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Quist H, Janbu J, Harbitz TB, Nesland JM (2004)
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells
In Clinical cancer research, AACR Publications Department, Philadelphia, PA, 10(2004)9, S. 3091-7
BIBSYS 05181322x

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist HL, Schlichting E, Sauer T, Janbu J, Harbitz TB, Naume B (2003)
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer
In Journal of clinical oncology, The Society, Alexandria VA, 21(2003)18, s.3469-78
BIBSYS 041728920

Anvar MD, Khiabani HZ, Nesland JM, Kroese A, Stranden E (2000)
Ultrastructural changes of the skin capillaries in chronical critical limb iscaemic oedema
In Journal of vascular research, Karger, Basel, 37(2000)Suppl.1, s.44
BIBSYS 010826068

0.24s